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CHAPTER ONE- INTRODUCTION
1.1

Breast cancer- a 2013 review
This section is meant to serve as a broad review of the breast and

breast cancer was information was compiled from Cancer.net, American
Cancer Society Breast Cancer Figures and Statistics, Arpino et al., VargoGogola et. al., Kleer et al., Simpson et. al., Kittaneh et. al., Wong et. al., and
Chabner and Longo.
It is estimated that one in every eight women will develop breast cancer
throughout the course of their life, with 232,340 new cases of invasive breast
cancer diagnosed in 2013 in the United States (American Cancer Society).
While researchers have identified a considerable number of risk factors, their
ability to accurately predict the development of invasive carcinoma is inadequate.
Currently, breast cancer is still the second leading cause of cancer death in
women, responsible for 1 in every 36 deaths. Therefore, extensive efforts have
been put forward to identify novel targets in this disease and develop drugs to
help treat patients once a diagnosis of invasive breast cancer has been
determined.
1.1.1 The normal breast
Breast cancer has many different forms and can arise from multiple cell
types within the breast. The breast is primarily composed of adipose tissue, and
throughout this adipose tissue is a vast network of specialized epithelial
structures that comprise the milk ducts and lobules. In addition to these ducts,
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there are also blood and lymph vessels that bring blood to nourish the cells and
drain waste products produced in the breast, respectively.
The main function of the human breast is to produce milk to nourish
newborns. Normal breast development occurs in three distinct stages throughout
a women’s life. The breasts begin to form in-utero where the mammary ridge
develops. The mammary ridge is a thickening of the chest wall. By infancy both
the nipple and milk-duct system have been formed. Near adolescence the breast
begins to change again. The milk ducts (pictured below) grow in a segmentally
branching pattern stemming from the nipple. Each of these branches forms
separate lobes within the breast. The lobes are separated from each other by
adipose tissue and are composed of stroma and lactiferous ducts. The stroma is
a network of supporting structures for the cells usually composed of connective
tissue. Each of these lactiferous ducts drains one lobe of the breast and leads to
the nipple. The development of these lobes, 15-24 in total, depends on
hormones, which are present first during puberty. Between the lobes, connecting
to the skin, are ligaments called Cooper’s Ligaments. These provide the support
to the breast. The final stage of breast development is involution, where the
breast tissue regresses back to a non-secreting form after lactation.

Figure 1: (Left) Shows histology of
human breast tissue including
adipocytes, alveoli, and ducts.
(Image reprinted with permission
from
proteinatlas.com
(Right)
Cartoon depicts the make-up of a
normal human breast. (Image
reprinted with permission from
Patrick J. Lynch (medical illustrator,
Yale University)
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Normal breast remodeling
Changes in hormone levels during the menstrual cycle lead to continuous
remodeling of the breast. Estrogen, which is produced during the first half of the
menstrual cycle, causes growth of the milk ducts. Once ovulation takes place
progesterone replaces the estrogen for the second half of the cycle, which
causes the formation of the milk glands. If the woman does not become pregnant
during the cycle, progesterone levels drop and the breasts return to normal size.
For this reason the breast tissue is constantly remodeling and turning over even
in normal breast tissue.
An even greater extent of remodeling occurs during pregnancy. As
mentioned above, progesterone is critical for the formation of milk glands. Once a
fertilized egg is implanted in the uterus, cyclical hormone production halts and
the body begins to continuously produce incrementally higher amounts of
progesterone instead of the levels tapering off to begin a new cycle. As the levels
of progesterone increase the milk glands continue to grow and as a result, both
epithelial and endothelial cell growth increases. By the fifth or sixth month of the
pregnancy, the breast structure has remodeled with a greatly increased number
of lobes and ducts, and the breast becomes capable of producing milk. Upon
termination of breast feeding the process of involution, or the shrinking of the milk
ducts and breasts, takes place and the breast tissue returns to normal size.
1.1.2 Breast cancer types
Non-invasive and Invasive ductal carcinoma
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The vast majority of breast cancers diagnosed originate in the ductal
epithelium and are either non-invasive or invasive at the time of diagnosis.
Ductal carcinoma in situ (DCIS) is the most common type of non-invasive breast
cancer. DCIS is considered non-invasive because it has not penetrated the
basement membrane and invaded beyond the milk duct into the surrounding
tissue. Physicians will commonly recommend frequent check-ups for patients
with DCIS since it increases the risk of developing an invasive breast cancer in
the future. Occasionally physicians will perform a lumpectomy to remove the
DCIS (discussed later), but in general a diagnosis of DCIS does not usually
require treatment. Once the cancer cells break through the basal membrane of
the ducts and into the surrounding tissues and/or lymphatics it is considered an
invasive ductal carcinoma (IDC). IDC can be diagnosed at many distinct stages
(discussed later in breast cancer staging) but if left untreated can metastasize to
distant parts of the body. Once metastases have occurred, the five year survival
rate drops from 88% down to 15%.

Figure 2: Depiction of the
progression
to breast
cancer.
DCIS
occurs
when cancer cells block
the milk ducts but do not
invade through them. IDC
occurs when the cancer
cells invade out of the milk
ducts into the surrounding
tissue. If left untreated,
IDC will metastasize to
distant part of the body.
Image
reprinted
with
permission from VargoGagola et al., 2007.
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Subtypes of invasive ductal carcinoma
Within the diagnosis of IDC there are various subtypes of tumors with
specific properties that can determine prognosis and treatment for the individual.
Hormone receptor status is arguably the most important of these properties. The
presence of the progesterone receptor (PR), estrogen receptor (ER) and the
human epidermal growth factor receptor 2 (HER2), two hormone receptors and a
commonly amplified growth factor receptor respectively, are determined after
diagnosis to accurately screen for phenotypic variation and to estimate
prognosis. Several drugs that selectively target the hormone receptors and
therefore curb the growth of the tumor with limited systemic cytotoxic effects are
available. These targeted therapies (discussed in section 1.3) have led to better
prognoses for patients whose tumors express one or more of these receptors.
Tumors that do not express any of these three receptors are commonly referred
to as triple negative tumors. These patients have a poor prognosis and suffer
from a very aggressive and invasive phenotype. Along with analyzing hormone
status, physicians also look at the morphology of the tumor to properly diagnose
and determine a course of treatment.
Medullary, papillary and tubular breast cancer
One form of breast cancer with a unique morphology is medullary
carcinoma. This type of breast cancer starts in the ducts but has a very different
morphology from non-medullary IDC. Medullary IDC is more profuse with a large
fleshy mass that comprises the tumor and is characterized by an extensive
lymphocytic infiltration. Another rare form of IDC is mucinous breast carcinoma,
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characterized by pools of mucin which encapsulate the cancer. Papillary and
tubular breast carcinomas are two more types of IDC that are very similar to each
other. Papillary carcinoma is usually a well-defined tumor with finger-like
projections whereas tubular carcinoma presents with cancer cells forming tubelike structures in the breast. Medullary, mucinous, papillary, and tubular IDC are
very rare types of breast cancer and together account for about 10% of all
invasive ductal carcinomas. In general, these four types of IDC are slower
growing and less aggressive than triple negative IDC or the other more common
forms of IDC.
Inflammatory breast cancer
Another rare type of breast cancer is inflammatory breast cancer (IBC). While
IBC is only responsible for 1-3% of all diagnosed breast cancers, it has the most
aggressive phenotype. Due to its rarity and presentation that is distinct from IDC,
the awareness about this subtype of breast cancer is generally low. While IDC
usually presents as a lump in the breast, IBC usually presents as a red, inflamed
breast, which is often warm to the touch. Patients with this disease can also have
unusual skin appearance, called “peau d’orange” stemming from the skin’s
resemblance to an orange peel. IBC is commonly misdiagnosed as mastitis, a
bacterial infection of the breast. For this reason, as well as a lack of information
among the general population about this type of breast cancer, patients are
usually diagnosed at a later stage and have only a 34% five-year survival rate.
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Figure 3: Image shows lymphatic
ducts blocked by epithelial carcinoma
cells in the dermis of the breast. This is
a hallmark of the aggressive type of
breast cancer called IBC. Most IBC
tumors are positive for the epithelial
marker E-cadherin as shown by
immunohistochemistry in the lower
panel. Image reprinted with permission
from Kleer et al., 2001)

One of the defining characteristics of this type of breast cancer is tumor
emboli (Figure 3). A distinguishing feature of IBC compared to IDC is the fact that
the cancer cells are blocking the lymphatic vessels in the breast. These
lymphatic vessels are responsible for transporting waste products out of the
breast. When these are blocked as in IBC, inflammation and swelling occur.
Adding to the difficulty of early diagnosis is the fact that IBC does not generate
the typical lump in the breast and can typically not be detected by palpation,
mammography or ultrasound examination.
Infiltrating lobular carcinoma
Another type of breast cancer is infiltrating lobular carcinoma (ILC). Many
times “infiltrating” is used interchangeably with “invasive” for many types of
cancer. ILC is more common than IBC but less common than IDC, and is
responsible for approximately 10% of breast cancers. This type of breast cancer
features small cancerous cells that originate in the lobules and infiltrate the tumor
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stroma. This type of breast cancer does not typically form a mass nor does it

Figure
4:
Image
shows
the
characteristic mark of ILC: The single
file carcinoma cells invading the tumor
stroma (shown with arrows). Image
reprinted
with
permission
from
breastpathology.net

destroy the features of the surrounding breast tissue.
Due to the distinct growth patterns and the absence of a well-defined
mass this type of carcinoma is difficult to detect early and is hard to treat with
surgery. ILC invades the surrounding stroma in uniform single lines. This type of
invasion makes the detection on mammography or other screening modalities
extremely difficult; usually a biopsy is used to make a diagnosis of ILC. Typically
a diagnosis of ILC carries a good prognosis.
1.1.3. Breast cancer diagnosis, staging and treatment
Breast cancer screenings
Many advances have been made in the past decade in detecting breast
cancers at earlier stages. In addition to self-breast exams, the most effective tool
physicians have is mammography screening. Mammography uses a low energy
X-ray to image the breast. A radiologist then examines the images to look for any
early signs of breast cancer. Since mammography became readily available in
the 1990s, the number of women who die of breast cancer has decreased by
almost 30%. Detecting breast cancer at an early stage vastly increases the odds
of survival. The NIH recommends that women receive a mammography every
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two years between the ages of 50 and 74. However, mammography has a
substantial false-positive rate of about 7%. There are various reasons for falsepositives; some women naturally have denser breasts, which makes it difficult for
the radiologist to determine if the tissue is normal or cancerous. Other times the
lump detected by mammography can be a benign case of breast disease, which
requires no course of action.
If screening mammography results are positive, an ultra-sound, magnetic
resonance imaging (MRI) or a diagnostic biopsy will be performed. An ultrasound
uses sound waves to produce an image. Ultrasounds are often used to help the
physician determine if a biopsy is needed or if the breast appearance on
mammography was likely secondary to a benign high density compartment of the
breast. Finally, MRI uses a strong magnetic field to produce an image. Similar to
an ultrasound in diagnostic use, an MRI can either confirm the need for biopsy or
suggest a lesion that is likely to be benign. For diagnostic biopsies a small
amount of the tissue in question is removed and sent to a pathologist to
determine if cancer cells are present. This is usually a minimally invasive
procedure and can confirm or refute a diagnosis of cancer.
Breast cancer staging and treatment determination
The treatment of breast cancer is typically dependent on five major
factors: 1) grade and stage upon diagnosis, 2) hormone receptor status, 3) Age
and general health of the patient, 4) pre/post-menopausal status and 5) presence
of known mutations within the tumor.
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The three grades of a tumor are characterized by the morphology,
especially the level of differentiation and the size and shape of the nucleus in the
tumor cells, of the individual cancer cells when observed under the microscope.
Grade one, or low grade means, that their morphology is very similar to the
normal breast cells (well differentiated with small nuclei). If the cancer cells are
growing at an accelerated rate compared to the normal breast cells it is
considered a grade two tumor (moderately differentiated with moderate nuclear
pleomorphism. If morphologically the cancer cells appear very different from the
normal breast cells and are growing quickly, it is considered a grade three or a
high-grade tumor (poorly differentiated with pronounced nuclear pleomorphism).
While grading is based on microscopic observation, staging combines two
nomenclature systems. The first is a number-staging system. Briefly, stage one
tumors are less than or equal to 2 cm and are localized to the site of primary
origin (in this case the breast), stage two tumors are either larger than stage one
or cancer cells can be detected in the nearby lymph nodes, stage three refers to
a tumor is larger than stage 2 and/or has spread to nearby tissues and lymph
nodes, and finally a stage four tumor indicates that the cancer has metastasized
or spread to distant parts of the body. Combining this number system with the
TNM staging system gives a complete picture of the tumor status in a patient. T
describes the size of the tumor, so for example a T2 tumor would mean that the
tumor was greater than 2 cm but less than 5 cm. The N in the TMN staging refers
to the lymph node status. There are only two choices in the N stage, either N0 or
N1. N0 means there are no cancer cells present in the lymph nodes where their
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presence is detected in N1. Finally, the M refers to the presence of metastases
again with only the choices of M0 or M1.
As mentioned, tumors are also analyzed for their hormone receptor status.
The PR, ER and HER2 receptors mediate signaling that control breast cancer
cells ability to grow and divide. Since most types of breast cancers (with the
exception of triple negative breast cancers) express one or more of these
hormone receptors, these tumors may allow treatment with a low-toxicity targeted
therapy that selectively blocks the signaling through these individual receptors.
Physicians also take into consideration the overall health and age of the
patient. Even targeted therapy can have substantial adverse effects when
combined with more toxic chemotherapy drugs to completely eliminate the
cancer resulting in debilitating-treatment related side-effects. The overall health
of the patient may help determine whether they will be able to tolerate the most
aggressive treatments or if a less aggressive treatment regimen would be
advantageous.
The fourth factor is whether or not the patient has gone through
menopause. Post-menopausal women generally have a higher risk for
developing hormone independent types of breast cancers than pre-menopausal
women. If the patient is of childbearing age a physician will be less likely to
prescribe hormone therapies or other therapies that may permanently impact
pregnancy or pregnancy-related outcomes. Drugs that affect estrogen production
are not tolerated as well by pre-menopausal women compared to women who
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have already gone through menopause so physicians generally use antiestrogen therapies sparingly in pre-menopausal patients.
The final factor to take into consideration when determining a course of
treatment for a patient is whether or not they have any known genetic mutations
within the tumor. Breast cancer cells are able to utilize many pathways to grow
and drugs have been developed to specifically block some of these pathways. A
common mutation in tumors is overexpression or the activation of a growth factor
receptor without the presence of a ligand (i.e. BRCA1 and BRCA2 mutations).
While normal cells typically require the presence of a receptor ligand to control
growth factor signaling, cancer cells may exploit these growth factor receptor
transduction pathways to signal for aberrant growth and proliferation. Many
antibodies are used in the clinic to neutralize the receptor and decrease tumor
burden. Identification and testing for common markers of breast cancer allow
physicians to tailor a specific treatment to each individual patient to provide the
best outcome.
Treatment types
Surgery
A common course of action for tumors that are contained within the breast
and have not invaded surrounding tissues (early stage) is surgical resection of
the tumor. Two surgical procedures are commonly used to remove tumors in the
breast based on the size of the tumor. A lumpectomy removes just the tumor and
a small amount of normal surrounding breast tissue to ensure clean margins. A
mastectomy is more aggressive and involves the removal of the whole breast
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and some underlying muscle tissue. Usually physicians will recommend adjuvant
chemotherapy after surgery to ensure any cancer cells left behind are killed. This
adjuvant therapy can include radiation, chemotherapy, targeted therapy and/or
hormonal therapy.
Radiation
Radiation is the adjuvant therapy typically given to patients who have had
a lumpectomy. This type of therapy is normally given for a set number of weeks
to lower the number of residual cancer cells after the surgery that may cause
cancer recurrence. Although there are side effects of radiation therapy, modern
advances in medical physics have made radiation therapy much safer. In certain
circumstances physicians may recommend radiation therapy as the primary
course of treatment instead of surgery. This normally occurs if the tumor is slow
growing and/or there are other circumstances, which make surgery a less
attractive option.
Chemotherapy
Chemotherapy is often used alone but can also be prescribed after
surgery. Multiple drug regimens are usually mixed and given systemically to
reach cancer cells throughout the body. Although there are many different
chemotherapy drugs, most can be categorized in the following main classes: 1)
Antifolates 2) Alkylating Agents 3) Antimitotic Drugs 4) Platinum Analogs 5)
Cytidine Analogs 6) Purine Antimetabolites and 7) 5-Fluoropyrimidines. These
seven different classes of chemotherapeutic agents all have different
mechanisms of action but most all target deoxyribonucleic acid (DNA) replication
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and repair and subsequently cause apoptotic cell death. Unfortunately,
chemotherapeutic drugs are unable to selectively target cancer cells and are
toxic to actively replicating cells in the body. This leads to the common side
effects of chemotherapy including hair loss, low blood cell counts and GI toxicity
as the hair follicles, bone marrow and GI lining represent some of the body’s
most rapidly dividing normal cells. However, as cancer cells are more rapidly
replicating their DNA the drugs preferentially affect the cancer cells over the
normal cells.
The antifolate class of drugs was discovered in 1947 by Dr. Sidney Farber
who developed the common anti-leukemia drug, aminopterin. Drugs within this
class are effective against cancer cells because they interfere with purine and
thymidylate synthesis. By depleting the store of DNA precursors within the cells,
the cells cannot replicate their DNA accurately and undergo cell death.
The alkylating agents class covalently add alkyl groups to DNA through
the formation of reactive oxygen species causing DNA strand breaks. These alkyl
groups prevent the DNA repair mechanisms from being carried out within the cell
in response to misreplicated DNA. Therefore, the integrity of the DNA is
compromised triggering apoptosis.
The antimitotic drugs have a slightly different way of affecting DNA
replication. Unlike the previous classes of drugs, which affect DNA replication
during the G2/S phase of the cell cycle, antimitotic drugs disrupt the microtubules
during mitosis leading to apoptotic cell death. The microtubules are responsible
for pulling apart sister chromatids in the mitotic cells, one into each of the
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daughter cells. If the microtubules are inhibited the genomic stability of the cells
is compromised and apoptosis is triggered.
The next set of drugs is the platinum analogs. These drugs covalently bind
purine bases together forming DNA adducts. When these DNA adducts
accumulate faster than repair mechanisms can repair them the cells typically
become apoptotic. Similar to these analogs are the cytidine analogs that mimic
the DNA base cytosine and get incorporated into elongating DNA strands. These
analogs inhibit DNA polymerases from extending the chain any further which
compromises genomic integrity, killing the cell. The purine antimetabolites also
incorporate into the elongating DNA strand. These drugs cause DNA mutations
because the purine analogs pair with an otherwise non-complementary DNA
base causing the mutation to be propagated. The accumulating mutations result
in stress on the cell, which eventually leads to apoptosis. The final class of
chemotherapy drugs is the 5-fluoropyrimidines. These drugs mimic RNA and
DNA components and trigger DNA strand breaks. Once these breaks accumulate
apoptosis is triggered.
Targeted/hormonal therapies
Since the drugs described above affect the replication of DNA in normal
non-cancerous cells, it is not surprising that there are many side effects from
using chemotherapeutic agents. Most chemotherapeutic agents are very
neurotoxic and myelosuppressive causing neuropathy and muscle weakness in
patients. Other common limiting toxicities for standard chemotherapy are the
damage they do to cells in the kidneys and liver. Since even otherwise healthy
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patients may become ill while receiving chemotherapy, research is focused on
developing drugs to more selectively target cancer cells, thereby reducing the
toxic side effects seen with standard chemotherapy. As mentioned previously,
there are three common signaling receptors, ER, PR, and HER2, that are
common in breast tumors. Many targeted therapies such as trastuzumab
(monoclonal anti-HER2 antibody) inhibit a single receptor or ligand to reduce the
growth signaling in the cancer cells. Another common type of a “targeted
therapy” is hormonal therapy. This is often given to women past childbearing age
but is also used when tumors are positive for ER and/or PR as a second line of
treatment if they do not respond to initial chemotherapeutics. An example is
tamoxifen, a selective estrogen receptor modulator, that blocks estrogen from
binding to ER and PR. Anti-angiogenic therapies are also often used to treat
breast cancer. Drugs in this class, like bevacizumab, target the growth of new
blood vessels. These vessels are required to supply blood and nutrients to the
tumor while allowing the cancer cells to metastasize to different areas of the
body. Such cell-selective targeted therapies typically have a relatively favorable
adverse effect profile but are not without side effects. However, in general they
are frequently less detrimental to the health and are often a more attractive
choice when compared to standard chemotherapeutics, especially when health
or age concerns do not allow for the most aggressive treatments.
While much progress has been achieved in treating and diagnosing breast
cancer, especially regarding early detection, there were still roughly 40,000
women that died of this disease in 2013 in the United States and there remains a
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substantial need to identify new therapeutic targets and to develop more effective
agents to help women once this devastating diagnosis has been made.
1.2 Proteases involved in breast cancer.
As described above, the breast (mammary gland in mice) is a highly
dynamic organ, which undergoes growth and remodeling during pubertal
development and subsequently as the gland adapts to the physiological
requirements

of

lactation

and

postlactational

involution.

These

normal

developmental and morphogenic events are believed to influence the
susceptibility of the mammary gland to carcinogenesis in both mice and humans.
Several classes of proteolytic enzymes have been implicated in mammary
gland development and in the progression of preneoplastic and neoplastic breast
lesions. It is widely believed that carcinogenesis often involves developmental
pathways, including proteolytic pathways, that have gone awry in breast cancer.
The vast majority of studied proteases are expressed in the mesenchymal
compartment (e.g. fibroblasts and inflammatory cells) of the healthy mammary
gland and in the stromal compartment of breast tumors, whereas others are
expressed by epithelial cells. Below is a brief description of the protease classes
most studied in connection with breast development and carcinogenesis. This
section will focus on serine proteases, and specifically type II membrane
anchored serine proteases, and provide a review of the literature that describes
the roles of these enzymes in health and disease, including cancer.
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1.2.1 Classes of proteases – a brief overview
Proteases were first described in 1905 as enzymes that cleaved other
proteins (Levene et al. 1905). Today it is known that the human genome encodes
at least 569 proteases. Based on the mechanism of catalysis, proteases are
classified into five distinct classes: 1) aspartate proteases 2) threonine proteases
3) metalloproteinases 4) cysteine proteases and 5) serine proteases. The names
of the classes refer to the amino acid residue used in their active site, except the
metalloproteinase class, where the name refers to the zinc in the active site that
interacts with a conserved cysteine residue. Proteases in general share a
mechanism of performing a nucleophilic attack on the carbonyl-carbon of an
amide bond (Chapman et al. 1997). Different types of proteases use different
mechanisms to achieve this, but an irreversible cleavage of an amide bond is the
end result for all these protease families. The ability of a tumor to metastasize
into a distant site is directly related to its ability to invade into the surrounding
tumor stroma and eventually into the blood stream and lymphatics (Mason et al.
2011). Historically, proteases have only been considered to play roles in the
degradation of the extracellular matrix during cancer cell invasion, however in
recent years they have gained attention for playing critical roles in many different
processes in carcinogenesis including proliferation, apoptosis, signaling,
migration and protein quality control. There have been a multitude of proteases
studied in relation to breast cancer and this section introduces proteases and
reviews previous protease studies.
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Figure 5: Graphical representation of
the five classes of proteases in
humans. Metalloproteases is the
largest class with 194 members,
followed by serine proteases with 176
members, cysteine protease class
with 150 members, threonine protease
class with 28 members, and the
aspartate proteases with 21 members.
Numbers on the left correspond to the
number of intracellular proteases and
the numbers on the right correspond
to extra or pericellular proteases within
the classes. Image reprinted with
permission from Lopez-Otin et al.
2007.

1.2.2 Intracellular proteases
Each of the five main classes of proteases have members that are
classified as intracellular proteases, members that are extracellular proteases,
and some that may function either intracellularly or extracellularly depending on
the cell types and circumstances. Typically, researchers associate intracellular
proteases with the removal of damaged or harmful products from the cell (LopezOtin et al. 2007). These include lysosomal cysteine and aspartate cathepsins
which aid in the degradation of damaged proteins in the cell. There are three
main families of intracellular proteases: 1) caspases 2) deubiquitinases and 3)
autophagins. The caspases are a family of cysteine proteases that play a crucial
role in programmed cell death or apoptosis. One of Weinberg’s “Hallmarks of
Cancer” is the dysregulation of apoptosis and many studies have focused on
alterations of caspases in malignancies (Hanahan et al. 2011, Teitz et al. 2000).
Caspase 8 was at the forefront of caspase research when it was found to be
epigenetically silenced in neuroblastomas, which overexpressed the MYC
oncogene (Teitz et al. 2009). Caspase 8 was subsequently shown to be silenced
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in many other tumor types and this silencing confers an increased risk of
metastasis (Stupack et al. 2006). Caspases 3, 5, 6, 7, and 10 have also been
found to be dysregulated or mutated in human tumors but it is unclear whether
the mutations are the driving mutation or whether the mutations occur due to
genomic instability once the cell is transformed (Park et al. 2002, Soung et al.
2004, Offman et al. 2005, Lee et al. 2006, Soung et al. 2003).
Protein quality control is imperative to cells in order to perform normal
biological functions. The second major family of intracellular proteases,
deubiquitinases (DUBs), is responsible for a large part of protein quality control in
the cell. DUBs can be either cysteine proteases or metalloproteinases and are
responsible for detaching ubiquitin from proteins that have been tagged for
degradation and have been identified as tumor suppressors (Lopez-Otin et al.
2007). The cylindromatosis gene (CYLD), is a DUB that is mutated in patients
with familial cylindromatosis, which causes tumors of skin appendages (Bignell et
al. 2000, Lopez-Otin et al. 2007). CYLD’s normal function; that is linked to limiting
tumor progression, is to deubiquitinate components of the nuclear factor-кB
(NFкB) pathway e.g. tumor necrosis factor (TNF) and B-cell lymphoma 3 (BCL3)
(reviewed in Simonson et al. 2007).
The final major family of intracellular proteases is the autophagins. These
are cysteine proteases responsible for the cell death process called autophagy.
Typically thought to be a response to overwhelming cellular stress, autophagy
has now been shown to be a tumor suppressive mechanism that cells undergo
when genomic stability is compromised (Marino et al. 2007). More research
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needs to be conducted to further elucidate the role of the autophagins. However,
autophagin 3 (Atg4c) is knock-out mice display a higher incidence of
fibrosarcomas, indicating that this autophagin is a tumor suppressor protease
(Marino et al. 2007).
1.2.3 Extracellular proteases
The second class of proteases are the extracellular proteases, meaning
their catalytic function occurs outside of the cellular membrane. The extracellular
proteases can be divided into five different families 1) matrix metalloproteinases
(MMPs), 2) a disintegrin and metalloproteinase or a disintegrin and
metalloproteinase with thrombospondin motifs (ADAM/ADAMTSs), 3) cathepsins,
4) aspartate and threonine proteases and 5) serine proteases. These
extracellular proteases play a wide variety of roles in development and
homeostasis, as well as disease. The first four families will be briefly described
below along with a more comprehensive focus on the serine proteases.
The family of MMPs can be further divided into three distinct but not all
encompassing groups: 1) The collagenases consisting of MMP-1,8,13, and 14,
2)The stromelysins containing MMP-3,7, and 10, and 3) The metalloelastases,
containing MMP12. There are 24 members in this entire family and many of the
members have redundant functions (Brinckerhoff 2002). Thirteen of the MMPs
are secreted proteases, 7 of them are membrane anchored and 4 can be either
secreted or membrane anchored. A shared characteristic of all of the MMPs is
the ability to degrade all components in the extracellular matrix, which lends to
their role in tumor progression. Due to this function, the MMPs were initially
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thought to predominantly be involved in tumor invasion and metastasis by direct
cleavage of extracellular matrix components. Further implicating MMPs in
cancer, many different MMPs are documented as being overexpressed in a
variety of cancers (Liotta et al. 1980). It is now clear that MMPs play diverse roles
in tumorigenesis. A challenge that comes with classifying so many different
proteases in the MMP family is the fact that different MMPs are expressed in
different cellular compartments and cell types. All MMP members have been
detected in tumor tissue and about half have been confirmed to have an
association with cancer using genetic mouse models. The substrates of MMPs
include growth factors, cell surface receptors, adhesion molecules, protease
zymogens and cytokines which are all intimately linked to cancer progression. As
a result of MMP-mediated proteolytic cleavage, activation or inactivation of these
substrates

influence

key

processes

such

as

proliferation,

apoptosis,

inflammation, invasion and angiogenesis (reviewed in Fingleton et al. 2006).
MMPs in breast cancer will be reviewed later in the section in “Elucidating the
Role of Extracellular Proteases in Breast Cancer in-vivo”.
The ADAM and ADAMTSs families contain 22 and 19 members,
respectively. These proteases are closely related to the MMPs, however, genetic
deficiency models have shown that ADAM/ADAMT proteases, in contrast to
MMPs, are crucial for development and survival. Thus, several knockout models
have resulted in embryonic lethality (Edwards et al. 2008, Apte et al. 2009).
These severe phenotypes have implicated the ADAMs and ADAMTSs in
fundamental biological functions including organogenesis. Although some
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ADAMs are expressed in tumors, confirmation of a causal relationship has not
established (Lopez-Otin et al. 2007, Apte et al. 2009, Joyce et al. 2011). Many
ADAMTSs have been identified as potential targets for anti-angiogenic therapies.
The most studied ADAMTS in this respect is ADAMTS1. ADAMTS1 inhibits
angiogenesis by binding to the vascular endothelial growth factor (VEGF) which
dampens the ability of VEGF to bind its receptor, vascular endothelial growth
factor receptor (VEGFR)-2 which stimulates the growth of new blood vessels
(Luque et al. 2003). Lack of ADAMTS1 allows VEGF to bind to its receptor to
promote vascular growth in both humans and mice (Iruela-Arispe et al. 2003).
ADAMTS1 has been shown to be downregulated in breast, colorectal and lung
carcinomas, implicating it in the metastasis of these cancers (Lopez-Otin et al.
2007).
The next family of extracellular proteases is the cathepsins. There are 15
members in total, 2 serine cathepsins, 2 aspartate cathepsins and 11 cysteine
cathepsins. The cathepsins that have been most studied are the cysteine
cathepsins. Cysteine cathepsins are usually located in the lysosomes and are
typically considered intracellular. However, in malignancies several cysteine
cathepsins been shown to be secreted from cells (reviewed in Mason et al. 2011,
Sloane et al. 2013). The causal relationship between cysteine cathepsins and
cancer progression has been proven through inhibition studies or mutant mouse
models (Mohamed et al. 2006). Cathepsin K is a cysteine cathepsin expressed in
osteoclasts and inflammatory cells such as macrophages. This cathepsin has
received attention for its role in tumor metastasis to bone. Herroon et al. showed
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that cathepsin K activity is integral for prostate cancer cells ability to metastasize
to bone possibly by contributing to the activation of chemokine ligand 2 (CCL2)
and cytochrome oxidase subunit 2 (COX-2) related pathways (Herroon et al.
2012).
1.2.4 Aspartate proteases and threonine proteases
The aspartate protease family is a relatively small group of proteases that
have not been studied as extensively as the other classes. It encompasses
intracellular and extracellular proteases, however, the vast majority are
intracellular (reviewed in Mason et al. 2011 and Ghosh et al. 2010). The
aspartate proteases use an aspartate residue for catalysis of their peptide
substrates and are optimally active at acidic pH. While research is underway,
only limited information is available about this class of proteases as a whole. An
example of an aspartate protease is cathepsin D. This protease is localized in the
lysosomes of hepatocytes and is involved in insulin degradation (Ghosh et al.
2010). Another example of an aspartate protease is pepsin. Pepsin is one of the
principal proteases that aid in the digestion of food in the gut (Ghosh et al. 2010).
Threonine proteases use a threonine residue in their active site and the
prototypic members of this class of enzymes are the catalytic subunits of
the proteasome. These components of the proteasome are located in both the
cytoplasm and nucleus of eukaryotic cells and function to degrade damaged or
misfolded proteins (Reviewed in Kruger et al. 2001).	
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1.2.5 Secreted serine proteases
Classically, secreted serine proteases have been associated with
biological processes like digestion, blood clotting and the complement system.
As this class of proteases has expanded, researchers are finding a wide variety
of novel functions, both in biological and pathological processes. A class of
protease inhibitors called serpins serves as endogenous regulators of proteolytic
activity for many members of the serine protease family.
One of the most studied secreted serine protease systems, not only in
breast cancer research but in a variety of biological processes including
thrombolysis/fibrinolysis and wound healing, is the urokinase type plasminogen
activator (uPA) and plasminogen/plasmin (plasminogen activation system).
Although it has the ability to cleave multiple targets, uPA’s primary physiological
substrate is the zymogen plasminogen, which is cleaved into the active serine
protease plasmin. Plasmin efficiently degrades thrombus-bound fibrin in the
vasculature as well as extravascular tissue fibrin. In order for the proform of uPA
(pro-uPA) to become activated it must be bound to its receptor, urokinase
plasminogen activator receptor (uPAR). Upon binding to uPAR, pro-uPA is
cleaved and activated by plasmin, thus creating a uPA/plasmin activation
feedback loop (Dano et al. 2005, Mason et al. 2011). The plasminogen activation
system demonstrates a complex interplay between the tumor cells and the tumor
stroma as uPA is expressed by stromal cells in the breast microenvironment
(including myofibroblasts and macrophages) and uPAR is expressed on stromal
cells and on epithelial- derived breast carcinoma cells. uPA and uPAR are over-
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expressed in the invasive areas of tumors and their microenvironments of the
breast, lung, esophagus, stomach and colorectum (Dass et al. 2008, Duffy et al.
2004, Gandolfo et al. 1996, Dano et al. 2005, reviewed in Degen et al. 2007).
This uPA/uPAR/plasminogen activation system has also been extensively
studied for its role in the degradation of the extracellular matrix (mainly fibrin)
allowing breast cancer cells to metastasize (Edwards et al. 1998, Mason et al.
2011, Qiu et al. 2007, Degen et al. 2007, Dano et al. 2005).
Another commonly studied family of secreted serine proteases is the
tissue kallikreins. This family contains 15 members that are expressed in a wide
variety of tissues. The most well-known member of this family is kallikrein 3, also
known as prostate-specific antigen (PSA). PSA is used as a biomarker in men for
early detection of prostate cancer or as an indicator of prostate cancer
progression (Diamandis et al. 1998). Although the biology of the kallikrein
proteases is incompletely understood, numerous studies show they are
dysregulated in cancers. In addition to kallikrein 3, kallikreins 2 and 11 are also
emerging as potential biomarkers for prostate cancer and kallikreins 5, 6, 7, 10,
11 and 14 have shown promise as predictive factors in ovarian cancer. In
addition, studies have revealed kallikrein 6 as being activated in the early events
of squamous cell carcinogenesis (reviewed in Paliouras et al. 2007).
1.2.6 Membrane anchored serine proteases
All members of the membrane anchored serine protease family have a S1
peptidase catalytic domain and many have been shown to play integral roles in
tissue homeostasis and disease including cancer progression (Rawlings et al.
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1993, Bugge et al. 2009). These proteases are synthesized as inactive
zymogens and must undergo a cleavage event to become functionally active
enzymes. The membrane anchored serine proteases can be divided into three
groups based on the way they are tethered to the plasma membrane: 1) a
carboxy terminal glycophosphatidylinositol (GPI) anchor, 2) a carboxy-terminal
transmembrane

domain

(Type

I),

or

3)

an

amino

terminal

proximal

transmembrane domain (Type II). This dissertation project focuses on a specific
Type II transmembrane serine protease (TTSP), matriptase, and this review
details the TTSP family of proteases but briefly describes other membrane serine
proteases.
1.2.6.1 Type I transmembrane serine proteases
The only known type I transmembrane serine protease is tryptase-γ1. This
protease is expressed exclusively in cells of the hematopoietic lineage and has
been most studied in mast cells (Reviewed in Antalis et al. 2011). The carboxyterminal signal anchor domain causes it to be retained on the outside of the cell
when mast cells are stimulated to release their secretory granules. Since mast
cells play a large role in immunosurveillance, they have been implicated in
asthma as well as other pathological conditions (Antalis et al. 2011).
Recombinant tryptase-γ1 in the trachea of mice induces an increased expression
of interleukin-13 (IL-13) in fluids of the lungs and airway hyper-responsiveness
(Caughey et al. 2007). Beyond this, the physiological functions of tryptase-γ1
remain unknown.
1.2.6.2 GPI anchored serine proteases
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There are two proteases in this group, testisin and prostasin. Both of these
proteases are anchored to the membrane via a GPI anchor that is added
posttranslationally in the endoplasmic reticulum. Testisin (PRSS21) was initially
discovered by Hooper et al., in 1999 as a tumor suppressor expressed in the
germ cells in the testis and in eosinophils. One biological function of testisin is to
induce maturation of spermatozoa and their fertilizing ability. In testisin deficient
mice, spermatozoa have decreased mobility and abnormal morphology (NetzelArnett et al. 2009). In cancer, it has been shown that epigenetic silencing of the
testisin gene promotes testicular carcinogenesis (Manton et al. 2005).
Conversely, in ovarian cancer, increased testisin levels have been correlated
with increased tumor stage (Shigemasa et al. 2000). When ovarian cancer cells
lines overexpressing testisin are injected into severe combined immunodeficient
mice the tumors grow larger and at a faster rate (Tang et al. 2005). More work is
needed to determine the molecular mechanisms by which testisin influences
testicular and ovarian carcinogenesis.
Prostasin is also known as channel-activating protease 1 (CAP-1) since it
was initially found to activate epithelial sodium channels (Vallet et al. 1997).
Prostasin is more widely expressed than testisin and has been found in the
epithelial cells of the prostate, colon, lung, kidney, pancreas, salivary gland, liver
and bronchi (Yu 1994). Interestingly, similarly to testisin, prostasin levels have
been found to be lost in prostate cancer but upregulated in ovarian cancer.
Studies assessing prostasin levels in serum of ovarian cancer patients that have
undergone oophorectomy suggest that prostasin is shed from the surface of
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ovarian cancer cells and may be a candidate for an ovarian cancer biomarker
(Costa et al. 2009, Mok et al. 2001, Chen et al. 2004). In addition to its
implications in ovarian and prostate cancer, levels of prostasin have also been
shown to be down-regulated in bladder and colorectal cancers (Chen et al. 2009,
Selzer-Plon et al. 2009)
Particularly relevant to this work, the type II transmembrane serine
protease matriptase is the physiological activator of the pro-form of prostasin in
the epidermis (Netzel-Arnett et al. 2006). Recent studies have suggested, that in
certain cells/tissues there is a complex reciprocal activation mechanism between
the two proteases (Szabo et al. 2012, Friis et al. 2013). Another study has placed
prostasin upstream of matriptase in a critical pathway involving activation of
protease activated receptor-2 (PAR-2) in neural tube closure (Camerer et al.
2010). Cell culture studies have revealed that prostasin has the ability to cleave
the epidermal growth factor receptor(EGFR), however, the physiological
relevance of this cleavage has yet to be determined (Chen et al. 2008, Chen et
al. 2009). Finally, prostasin has also been implicated in breast cancer as part of a
matriptase-prostasin proteolytic cascade and prostasin is co-expressed with
matriptase in the epithelial compartments of human invasive ductal carcinomas
(Bergum et al. 2011).
1.2.6.3 Type II transmembrane serine proteases
A new family of serine proteases has emerged from the Whole Genome
Sequencing project that was completed at the turn of the century. The Type II
Transmembrane Serine Protease (TTSP) family contains 17 known members in
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humans and each have an intracellular N-terminal signal anchor domain and an
extracellular C terminus, which contains a serine protease domain. Each member
of this family contains varying other domains, which make up the stem region,
whereas the N-terminal signal anchor and the C-terminal serine protease
domains are characterizing features of this family (Bugge et al. 2009, Antalis et
al. 2013). [Figure 6] In contrast to many other types of serine proteases (i.e. the
plasminogen activation system and several cathepsins) TTSP’s have been
shown to be mainly involved in maintaining homeostasis rather than returning the
tissue to homeostasis after tissue damage (Bugge et al. 2009). In addition to
maintaining homeostasis, matriptase has been shown to play a crucial role in
development. Knockout mouse models have shown that matriptase deficiency is
lethal due to malformed tight junctions in epidermal and intestinal epithelia (see
1.3.2 Physiological Functions) (List et al. 2002). The 17 members of the TTSP
family have been divided into four subfamilies: 1) Human airway trypsin-like
protease/differentially expressed in squamous cell carcinoma (HAT/DESC)

Figure 6: Depiction of all the
membrane anchored serine
protease. Shows the type I
transmembrane
serine
protease, tryptase-γ1, the
GPI anchored proteases
prostasin and testsin and the
entire family of type II
transmembrane
serene
protease. Figure reprinted
with permission from Szabo
et al. 2011.
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subfamily, 2) Hepsin/Transmembrane Serine Protease (TMPRSS) subfamily, 3)
Matriptase subfamily and 4) Corin subfamily.
HAT/DESC subfamily
The HAT/DESC subfamily is the least studied. This family has five
members in humans, HAT, HAT-like 4, HAT-like 5, DESC1, and TMPRSS11A.
The physiological substrates of these proteases are not well characterized,
however, the proteases have been showed to be upregulated during
inflammation and pathological processes such as carcinogenesis where
inflammation is present (Antalis et al. 2013). Mucus production, airway
maintenance, and cleavage of other proteases have all been proposed roles of
the HAT-like proteases (Webb et al. 2011). DESC1 was first studied in head and
neck carcinomas and found to be downregulated during carcinogenesis (Lang et
al. 2001). DESC1 has been shown to cleave many different components of the
extracellular matrix, including fibrin and collagen (Hobson et al. 2004, Antalis et
al. 2013). HAT proteases have been reported to activate PAR-2 as well as uPAR.
Furthermore, HAT can uncoat reovirus virions to promote infection in cell culture
models (Yoshinaga et al. 1998, Iwakiri et al. 2004, Nygaard et al. 2011, Baron et
al. 2012). Ongoing studies are exploring the potential of DESC1 as a therapeutic
target in some types of tumors (Webb et al. 2011) and HATL-5 has recently been
shown to be differentially expressed in epithelial tumors (Miller et al. 2014).
Hepsin/TMPRSS subfamily
This subfamily contains seven members, Hepsin, TMPRSS2, TMPRSS3,
TMPRSS4, TMPRSS5, TMPRSS13/mosaic serine protease long form (MSPL),
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and enteropeptidase. Hepsin was named due to its abundant expression in the
human liver, but is also expressed in the kidney, pancreas, stomach, prostate
and thyroid (reviewed in Antalis et al. 2013). Studies of knockout mouse models
of hepsin have demonstrated that this protease plays an important role in
cochlear development and that these mice also have low levels of the thyroid
secreted hormone, thyroxine (Guipponi et al. 2007, Antalis et al. 2013, Klezovitch
et al. 2004). It is still unclear if the low levels of thyroxine are linked to the
cochlear defects in the hepsin null mice (Guipponi et al. 2007). Hepsin also
appears to be crucially involved in prostate cancer metastasis. In 2004,
Klezovitch et al. used transgenic mice to show that the overexpression of hepsin
leads to a disorganized basement membrane and promotes prostate cancer
metastasis to the liver, bone and lungs (Klezovitch et al. 2004).
The physiological role of TMPRSS2 is currently unknown, however,a
protein resulting from a common fusion between the TMPRSS2 promoter and the
ERG (ETS-related gene) transcription factor has been shown to be highly
expressed in many prostate cancer patients. The TMPRSS2 androgen
responsive promoter drives an abnormally high expression of the ERG
transcription factor to promote tumor progression and invasion (Tomlins et al.
2005, Antalis et al. 2013).
TMPRSS3 was originally isolated as a protease that was overexpressed in
ovarian, pancreatic and breast cancer (Underwood et al. 2000). However,
TMPRSS3 also plays a crucial role in human autosomal recessive deafness.
Scott at el. was the first to show that mutations within the gene causes this
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condition in multiple families and it has now been demonstrated in over 20
families (Scott et al. 2001, Antalis et al. 2013). The mechanism by which
TMPRSS3 contributes to hearing remains unclear. TMPRSS4 mRNA has been
shown to be upregulated in several types of cancers, however, little is known
about its physiological functions. Regarding pathological functions, it has been
demonstrated that TMPRSS4 can activate influenza virus hemagglutinin and
promote infection (Chaipan et al. 2009). TMPRSS5 is also known as spinesin
and again, little is known about the physiological functions of this protease. In
expression studies mRNA was detected in rat inner ear tissues possibly
implicating

this

protease

in

hearing

function

(Antalis

et

al.

2013).

TMPRSS13/MSPL cleaves and activates the pro-form of the hepatocyte growth
factor (HGF) in vitro (Hashimoto et al. 2010, Szabo et al. 2011a). However, at
this time the physiological function of TMPRSS13/MSPL remains unknown and
its expression in cancer has not been described. The seventh family member
was discovered in the early 1900’s and has been extensively studied.
Enteropeptidase is located in the intestines where it converts pancreatic
trypsinogen into active trypsin, resulting in the subsequent activation of several
protease zymogens that are essential for food digestion and nutrient absorption.
Patients with enteropeptidase deficiency have impaired food digestion and many
suffer from malnutrition and anemia (Hadorn et al. 1975). Replacement therapy
with pancreatic extracts clinically restores that impaired proteolysis in the gut
(Antalis et al. 2013).
Matriptase subfamily
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This family only contains three family members: matriptase, matriptase-2
and matriptase-3. Despite their homology, each of these members appear to
have very different biological functions, likely due to the fact that the three
proteases display mostly non-overlapping expression patterns. Matriptase is
widely expressed in epithelial tissues and can undergo autocatalytic activation
(Takeuchi et al. 1999, Wu et al. 2003, Bugge et al. 2009, List et al. 2009, Szabo
et al. 2011a, Antalis et al. 2013). Matriptase was originally discovered in 1993 as
a new gelatinolytic activity in cultured breast cancer cells and subsequently
cloned in 1999 by three different groups (Shi et al. 1993, Takeuchi et al. 1999,
Kim et al. 1999, Lin et al. 1999). Matriptase will be further described in the next
section. Studies of matriptase-2 knockout mice have identified its important role
in iron metabolism. Matriptase-2 deficiency is the cause of the human autosomal
recessive disorder called iron-refractory iron deficiency anemia (Finberg et al.
2008). Matriptase-2 is expressed in hepatocytes and suppresses the function of
the hormone hepcidin, which is responsible for iron transport across the gut
mucosa. When matriptase-2 is absent, the levels of hepcidin increase the rate of
iron exported from hepatocytes is increased rapidly (Finberg et al. 2008, Antalis
et al. 2013). Matriptase-3, the final member of this subfamily, displays a restricted
expression pattern in human and mouse tissues (testis, ovary and eye) (Szabo et
al. 2011a). Interestingly matriptase-3 is also expressed throughout the central
nervous system (CNS), an organ system where no matriptase or matriptase-2
expression has been reported (reviewed in Antalis et al. 2013). The physiological
function of matriptase-3 remains unknown (Szabo et al. 2011a).
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Corin subfamily
This protease was named because it is abundantly expressed in the
human heart. In 2009 Wu et al. demonstrated that corin was the physiological
activator of the pro-atrial natriuretic peptide (pro-ANP). ANP is a hormone that
regulates cardiac function and blood pressure (Wu et al. 2009). Corin deficient
mice are hypertensive, have impaired cardiac function and develop cardiac
hypertrophy (Wu et al. 2009, Antalis et al. 2013). Human corin variants with
hypertension have been observed in the clinic and often develop accelerated
hypertension and cardiovascular disease (Dries et al. 2005). Corin is also
expressed in the pregnant uterus and plays a role in promoting trophoblast
invasion (Cui et al. 2012). Importantly, it has recently been shown that many
patients with preeclampsia have low levels of corin in the uterus, and corin gene
mutations in pre-eclamptic patients have been identified (Zhou et al. 2013).
1.2.7 Elucidating the role of extracellular proteases in breast cancer in vivo
Elegant studies using knockout mouse models for different proteases
demonstrate the crucial role of proteolysis during breast cancer progression. In
1997, Thomas Bugge et al. crossed a plasminogen (secreted serine protease)
deficient mouse model with transgenic mice that carried the polyoma middle T
antigen (PymT) oncogene that induces multifocal, bilateral mammary gland
tumors in female mice. In this model, PymT expression is under the
transcriptional control of the mouse mammary tumor virus (MMTV) promoter.
This MMTV-PymT model, which is further characterized by tumor metastasis to
the lung, will be further described in section 1.5.
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Plasminogen, once converted into the active serine protease plasmin, is
able to degrade fibrin as well as many other extracellular matrix proteins. (Bugge
et al. 1997). When the plasminogen deficient mice were crossed into the MMTVPymT model the authors were unable to detect a difference in the formation of
the primary mammary tumors in the plasminogen deficient mice compared to the
controls. However, the incidence of lung metastasis, the total number of
metastases and the total metastatic tumor burden in the plasminogen deficient
mice was significantly reduced. This finding implied that plasminogen could be a
viable drug target for antimetastasis therapy (Bugge et al. 1997).
A related study was conducted by Almholt et al. also used the MMTVPymT model, but this time crossed with uPA deficient mice. uPA together with
tPA are the main physiological activators of plasminogen. Again, these authors
found that uPA deficient mice did not have altered primary tumor growth,
whereas metastasis to the lungs was greatly reduced. This indicated that the
uPA protease was also a candidate antimetastasis target and the authors
suggested that inhibiting uPA may be less toxic than anti-plasminogen therapy
since uPA has fewer physiological targets than plasmin (Almholt et al. 2005).
The MMP’s have also been extensively studied in breast cancer
progression and metastasis and have been associated with diverse effects in
progression with some functioning as tumor suppressors whereas others have
pro-tumorigenic properties. Unfortunately, likely owing to their broad functional
roles, pan MMP inhibitors have largely failed in clinical trials due to off target
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effects and severe side effects (Martin et al. 2008, Reviewed in Coussens et al.
2002).
Martin et al. examined the role MMPs in an in vivo mouse model of breast
cancer, using the genetic MMTV-PymT model crossed with mice that were
deficient in either MMP7 or MMP9. These two MMP’s have very different
localization; MMP7 is located on the epithelial cancer cells whereas MMP9 is
expressed in inflammatory cells in the tumor microenvironment. When the
authors crossed the MMP7 deficient mice with the MMTV-PymT mice they
observed no difference in neither the primary tumor burden nor in metastatic
burden compared to the control mice. When MMP9 mice were crossed into the
tumor model, although there was no detectable difference in the tumor latency or
growth of the primary mammary tumors, the metastatic lung tumor burden was
significantly reduced. This suggests that inhibitors of MMP9 could have potential
utility as therapeutics to decrease the metastatic potential of the cancer cells in
breast cancer patients (Martin et al. 2008).
Sevenich et al. focused on two members of the cysteine protease class,
cathepsin B (ctsB) and cathepsin Z (ctsZ). Despite the cathepsins general
localization in the endosomal/lysosomal compartment, changes in distribution
during neoplasia are associated with secretion of these enzymes and resultant
extracellular effects. Interestingly, ctsB has been shown to relocate to the cell
surface of epithelial cells in cancer and plays a role in the degradation of the
extracellular matrix by activating plasminogen. Therefore they are included in this
section. These investigators crossed ctsZ null mice with ctsB null mice that also
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carried the PymT oncogene. Mice with double deficiency i.e. null for both ctsB
and ctsZ showed a significant delay in primary tumor growth as well as reduced
metastases to the lungs implying roles in primary breast tumor growth as well as
in progression. Interestingly, in this model both ctsB and ctsZ needed to be
simultaneously ablated to see the anti-cancer effects, potentially secondary to
functional overlap between the two proteases, which allows one to compensate
when the other is knocked out (Sevenich et al. 2010).
1.3 Matriptase
This work has focused on the TTSP matriptase. This transmembrane serine
protease has recently emerged as a protease with oncogenic properties. As
described below, matriptase has been implicated in many types of epithelial
cancers and this study sought to specifically investigate the role of matriptase in
breast cancer.

Figure 7: Schematic showing
matriptase in the cell surface.
Matriptase contains an Nterminal transmembrane domain,
a single SEA domain, two CUB
domains, four LDLA domains and
a C-terminal serine protease
domain.
Arrows
indicate
cleavage points.

1.3.1 Expression, structure and substrates
Originally isolated in 1993 from breast cancer cells, matriptase, also
known as ST14, contains an N-terminal signal anchor and a C-terminal serine
protease domain, which is located on the extracellular side of the cell (Shi et al.
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1993, Lin et al. 1997). In addition to these domains, matriptase also contains a
single sea urchin sperm protein (SEA) domain, two complement C1r/C1s, Uegf,
Bmp1 (CUB) domains and 4 low density lipoprotein A (LDLA) domains. Although
these domains are non-catalytic they appear to play crucial roles in the cellular
localization and the substrate specificity of the protease (Shi et al. 1993, Lin et al.
1997, Lin et al. 1999). Matriptase is synthesized as a single chain inactive
zymogen in the rough endoplasmic reticulum and is transported to the plasma
membrane through the Golgi apparatus (Takeuchi et al. 2000). The exact
mechanism(s) leading to matriptase activation are not well understood, but
requires two endoproteolytic cleavages (Figure 7) (Cho et al. 2001). The
zymogen must be cleaved after Gly149 in the SEA domain, which separates the
signal anchor domain from the remaining portion of the protease. However, the
protease remains tethered to the cell membrane by a non-covalent bond (Cho et
al. 2001). The second proteolytic cleavage occurs after Arg614 in the serine
protease domain. Once this cleavage occurs the protease domain remains
tethered to the rest of the protease by a disulfide bond (Figure 7). Once these
two cleavages have occurred matriptase is an active serine protease (Takeuchi
et al. 2000, Cho et al. 2001, List et al. 2006a). Importantly, matriptase has the
ability to autoactivate, a rare property among serine proteases (Lee et al. 2006).

40

Figure 8- X-gal stained tissue
pictures showing matriptase’s
expression (in blue). Matriptase
has been shown to the expressed
in the esophagus, bladder, hair
follicle, mammary gland, salivary
glands, uterus, trachea, jejunum,
cornea, kidney and bronchioles.

Matriptase is involved in various biological and pathological processes and
has a large variety of substrates of which only a few have been verified to be
relevant in vivo (see Physiological and Pathological Functions below). Matriptase
is expressed in epithelial cells throughout many tissues of the body, including
skin, cornea, salivary gland, oral and nasal cavities, thyroid, thymus, esophagus,
trachea, bronchioles, alveoli, stomach, pancreas, gall bladder, duodenum, small
intestine, colon, rectum, kidney, adrenals, urinary bladder, ureter, seminal
vesicles,

epididymis,

prostate,

ovaries,

uterus,

cervix,

vagina,

and

breast/mammary gland) (Figure 8). (Oberst et al. 2003, List et al. 2006a,b). In
addition to these epithelial cells, matriptase expression can also be found in
some types of immune cells, such as mast cells, monocytes and macrophages
(Bhatt et al. 2007, Cheng et al. 2007). Using a cell free approach matriptase is
able to cleave the inactive pro-forms of uPA, HGF, and to activate the G-proteincoupled PAR-2 (Lee et al. 2000, Takeuchi et al. 2000). In a 2007 study using
transcriptional profiling, additional substrates of matriptase were identified
including macrophage-stimulating protein 1 (MSP-1), a transmembrane protein
that is activated by src (TRASK), VEGFR-2 and insulin-like growth factor binding
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protein-related protein-1 (IGFBP-rP1) (Bhatt et al. 2007). The substrates that
have been identified for matriptase have diverse localizations and functions,
indicating that matriptase may play a key role in many molecular pathways.
However, only few substrates have been verified in vivo including the GPIanchored serine protease prostasin and pro-kallikreins in the epidermis (NetzelArnett et al. 2006, List et al. 2006a, List et al. 2007, Sales et al. 2014).
Matriptase has two cognate inhibitors, hepatocyte growth factor activator
inhibitor 1 (HAI-1) and HAI-2. Other inhibitors of matriptase have been identified
including antithrombin III, α-1-antitrypsin and α-2-antiplasmin; however, HAI-1
and HAI-2 are the only inhibitors that have been shown to be physiologically
relevant (List et al. 2006a, Nagaike et al. 2008, Szabo et al. 2008). Matriptase is
usually co-expressed with HAI-1 and HAI-2 and some researchers argue that coexpression with one of these two proteins is necessary for trafficking matriptase
to the cellular membrane, though this is still a controversial hypothesis (Wu et al.
2003, Oberst et al. 2005, Carney et al. 2007).
1.3.2 Physiological functions
Since matriptase is expressed in such a wide variety of epithelial tissues
as well as immune cells, determining relevant physiological roles for matriptase
involves analysis of a wide array of potential functions. Following matriptase’s
discovery, multiple genetic mouse models were created to learn about its
function in both development and disease. Knockout mouse models have proven
to be invaluable tools to determine the function of proteins, and the generation
and study of matriptase null mice provided important insights into matriptase’s
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function (List et al. 2002, List et al. 2003, List et al. 2007). In 2002 List et al.,
published a study that demonstrating that mice with a null deletion in both
matriptase alleles died one to two days after birth due to severe dehydration.
Matriptase was found to be critically involved in the formation of a functional
epidermis and matriptase null mice are unable to prevent water loss from
excessive evaporation through the skin. Further investigation led to the finding
that matriptase is also crucial for several processes that take place during
epidermal differentiation. These include lipid matrix formation in the cornified
layer, cornified envelope morphogenesis and the shedding of corneocytes (List et
al. 2002, List et al. 2006a, b). On the cellular level, matriptase deficiency affects
the processing of a major epidermal structural protein, profilaggrin, which
contributes to the skin impairments. Matriptase deficiency also causes the
thymus to be hypoplastic and prevents hair follicles from maturing (See Table 1).
Discussed more in the next section, humans with a missense mutation in their
matriptase alleles have skin abnormalities further verifying matriptase’s role in
the formation and maintenance of a functionally intact epidermis in humans.
(Basel-Vanagaite et al. 2007, Avrahami et al. 2008). Another physiological
substrate of matriptase is the pro-form of the GPI-anchored serine protease
prostasin. Gene ablation studies demonstrated that matriptase and prostasin
were both required for the formation of a functional epidermal barrier and the null
mice phenocopied one another (List et al. 2002, Leyvraz et al. 2005).
Subsequent investigation showed that prostasin was activated by matriptase in a
proteolytic cascade which regulates terminal epidermal differentiation (Netzel-
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Arnett et al. 2006). Since matriptase deficiency is perinatally lethal in mice, in
2009 List et al. generated a matriptase conditional knockout mouse using the
tamoxifen-inducible Cre/Lox system. These mice can fully develop before the
administration of tamoxifen ablates matriptase expression. (This model will be
described in detail in section 4.) However, knocking out matriptase at a later
timepoint in life was still lethal. List et al. demonstrated that the postnatal ablation
of matriptase led to severe organ dysfunction with increased permeability, loss of
tight junction function and general epithelial demise. These mice ultimately died
roughly two weeks after the ablation of matriptase due to the dysfunctional
epithelial structures and leaky tight junctions in the gut (List et al. 2009b).
Table 1:
Phenotypic characteristics of matriptase deficient mice:
Survival
Postnatal lethality
Body weight and body length
Reduced
External appearance of skin
Reddish & wrinkled
Hair follicles
Immature
Thymus
Hypoplastic
Inwards epidermal barrier function
Impaired
Outwards epidermal barrier function
Impaired
Corneocytes
Enlarged
Epidermal lipid composition
Abnormal
Filaggrin
Absent
Profilaggrin processing
Impaired
Epidermal differentiation markers
Normal
besides profilaggrin/filaggrin
Pro-prostasin activation
Absent
Tight junctions
Abnormal
Saliva production
Abnormal
Intestinal barrier function
Impaired
Compiled from List et al., 2002, List et al., 2003, Netzel-Arnett 2006, List et al., 2009

1.3.3 Pathological implications
There have been several reports describing mutations in the human
matriptase alleles causing two different hereditary syndromes: autosomal
recessive

ichthyosis

with

hypotrichosis

(ARIH)

or

ichthyosis,

follicular
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atrophoderma and hypotrichosis (Basel-Vanagaite et al. 2007, Avrahami et al.
2008). Patients with either of these conditions present with dry flaky skin and hair
follicle dysplasia, which is associated with brittle slow growing hair. Both
syndromes are indicative of an impaired skin barrier (Basel-Vanagaite et al. 2007,
Avrahami et al. 2008, Antalis et al. 2013). Furthermore, this syndrome was
phenocopied in a mouse model with low levels of matriptase (List et al. 2006b,
described fully in section 4.1) In 2010, Sales et al. demonstrated that matriptase
initiates a cascade that is linked to a mouse model of the human Netherton
syndrome. Netherton syndrome is an autosomal recessive form of severe
ichthyosis (Chao et al. 2005). In lympho-epithelial Kazal-type related inhibitor
(LEKTI)-deficient mice matriptase was found to initiate the inflammatory prokallikrein-related proteases that are associated with stratum corneum detachment
(Sales et al. 2010). LEKTI is a serine protease inhibitor and LEKTI deficiency
causes excessive proteolysis and detachment of the stratum corneum in patients
with Netherton syndrome (Chao et al. 2005, Sales et al. 2010). When the authors
ablated matriptase expression from the LEKTI deficient mice the inflammation and
symptoms of ichthyosis were diminished and the detachment of the stratum
corneum was inhibited. This indicates that the kallikrein cascade (associated with
Netherton syndrome) is dependent on activation by matriptase (Sales et al. 2010).
In addition to these skin-associated syndromes, matriptase is also being
actively investigated regarding multiple links to the pathobiology of cancer.
Matriptase has been implicated in cancer for over 2 decades since being detected
in breast cancer cells (Shi et al. 1993). In many types of cancers, expression
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studies have linked increasing matriptase levels to increasing tumor grade. This is
true for breast cancer, prostate cancer, ovarian cancer, colorectal cancer and
cervical cancer (Hoang et al. 2004, Saleem et al. 2006, Warren et al. 2008).
Based on these findings and the fact that matriptase is very tightly regulated by
HAI-1, several groups have analyzed the matriptase:HAI-1 ratio in tissues
hypothesizing that a higher matriptase to HAI-1 ratio would be indicative of a
higher grade tumor. Such a correlation has been verified for ovarian, prostate and
colorectal cancers (Vogel et al. 2006, Saleem et al. 2006, Oberst et al. 2002).
1.3.4 Defining the role of matriptase in cancer using genetic mouse models
A role for matriptase as a critical factor in cancer initiation was first
apparent with the generation of Keratin 5 (K5)-transgenic mice. This mouse model
of matriptase and its contribution to our current understanding related to the
physiological functions of matriptase and matriptase’s role in cancer progression
will be discussed next
List et al. in 2005 generated the K5 transgenic overexpression model of
matriptase. This model was developed in order to gain further insight into the prooncogenic properties that matriptase was hypothesized to have based on prior
observations showing its consistent up-regulation in epithelial tumors (Oberst et
al. 2001, Benaud et al. 2002b, Kang et al. 2003, Oberst et al. 2003, Wu et al.
2003). The authors designed the model to express the matriptase gene under the
K5 promoter which caused matriptase to be overexpressed exclusively in the
basal layer keratinocytes of the epidermis. List et. al., initially found that the
overexpression of matriptase in the keratinocytes of these mice was sufficient to
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cause spontaneous formation of squamous cell carcinomas. These tumors
occurred independently of ras activating mutations and caused an up-regulation of
the PI3K-Akt signaling pathway. This study demonstrated that matriptase is
critically involved in cancer progression and that it is expressed at all stages of
carcinogenesis (List et al. 2005). Furthermore, the spontaneous tumor formation
could be exacerbated by the application of the genotoxic chemical 7,12dimethylbezanthracene (DMBA). When a single dose of DMBA was applied to the
skin of K5-matriptase transgenic mice 95% of them formed tumors compared to
just 1.7% of the control mice. The skin tumors resulting from the DMBA
application were frequently accompanied by K-ras or H-ras mutations. Taken
together, these studies indicate that matriptase promotes both ras-independent
and ras-dependent malignant transformation (List et al. 2005).
Additional studies of the K-5 transgenic model demonstrated that in head
and neck squamous cell carcinomas, matriptase, is co-expressed withHGF) and
its receptor, c-Met. In addition, this study showed that the oncogenic potential of
matriptase in these tumors is dependent on c-Met expression. Thus, when the
investigators genetically ablated c-Met expression from the basal keratinocytes,
they found that matriptase no longer promoted malignant transformation (Szabo et
al. 2009a, b).
In addition to the initial matriptase null and matriptase K5 overexpression
mice (List et al. 2002, List et al. 2005), two additional mouse models have been
generated. The matriptase hypomorphic mice and the matriptase conditional
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knockout mice (List et al. 2006b, List et al. 2009) will be explained in detail in
section 4 on models used in the project.
1.3.5 Matriptase in breast cancer
Multiple studies have demonstrated the relationship between matriptase
expression and breast cancer patient outcome (Benaud et al. 2002b, Welman et
al. 2012, Charafe-Jauffret et al. 2006, Kang et al. 2003, Uhland et al. 2006).
Matriptase is expressed in most breast cancer cell lines, however, its role in vivo
and the molecular mechanisms and downstream signaling events underlying its
expression in these tumors are less clear. The previously described study in
squamous cells demonstrating that c-Met is essential for matriptase induced
malignant transformation established matriptase as an initiator of the c-Met
signaling cascade in the epidermis (Szabo et al. 2009a,b, Szabo et al. 2011b).
Aberrant growth factor receptor signaling is common to many malignancies
including breast cancer. In breast cancer the c-Met receptor is commonly
dysregulated, although most patients do not have an activating mutation in the
receptor itself (Szabo et al. 2011b, Uhland et al. 2006, Charafe-Jauffret et al.
2006). As mentioned, c-Met, its’ ligand (HGF/SF) and matriptase are all
expressed in the breast tumor microenvironment, and furthermore, all have been
correlated with a poor patient outcome (Ghoussoub et al. 1998, Charafe-Jauffret
et al. 2006, Camp et al. 1999). This expression of matriptase and c-Met and the
discovery that matriptase has the ability to cleave the inactive form of HGF (proHGF) into active HGF prompted this study to investigate the functional
relationship between matriptase and c-Met in breast cancer. (Lee et al. 2000).
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1.4 HGF/c-Met in breast cancer
Multiple studies highlight the importance of the tumor microenvironment in
breast cancer progression. However, mono-cell tumor culture models do not
recapitulate potentially crucial tumor-stromal signaling exchanges. For instance, in
ductal breast cancer, HGF is a mesenchymally derived growth factor and
paracrine mediator that affects the proliferation, differentiation, motility, and
invasiveness of the malignant ductal epithelial cells through an often dysregulated
c-Met: HGF’s tyrosine kinase receptor. In breast cancer patients this has been
identified as a key signaling pathway that has been targeted in breast cancer
therapeutics (Gherardi et al. 2012). In this section c-Met and HGF are reviewed
focusing on their relevance to breast cancer.
1.4.1 Localization and activation of pro-HGF and c-Met in breast cancer
Pro-HGF is secreted by mesenchymal cells, mainly fibroblasts in the breast, as a
single chain inactive enzyme that is unable to initiate the phosphorylation and
signaling through its receptor c-Met. Although c-Met can bind pro-HGF, a specific
cleavage event must occur converting pro-HGF into its two-chain active form for
c-Met signaling to commence (Birchmeier et al. 2003, Owen et al. 2010, Gherardi
et al. 2012). The c-Met receptor is located on the surface of epithelial cells within
the breast, creating crosstalk between the mesenchymal cells, which secrete proHGF, to the epithelial cells which express its receptor. Upon cleavage of pro-HGF,
the c-Met binding site on HGF’s alpha subunit is exposed which has a much
higher affinity for the receptor. Once this site binds to c-Met, cross
phosphorylation of the receptor and its subsequent signaling is induced (Naldini et
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al. 1995). This binding activates various signaling cascades through c-Met that
promote survival, mitogenic, motogenic and proliferative responses (Birchmeier et
al. 2003, Gherardi et al. 2012).

Figure 9: (Below) Schematic showing single chain
inactive HGF and the cleavage required to convert
HGF into its two chain activated form. (Right)
Picture showing the c-Met signaling pathway and
the possible cellular outcomes when the c-Met
receptor is activated. Image reprinted with
permission from http://pharmaxchange.info/.

Aberrant signaling of the c-Met oncogene is associated with poor patient
outcomes for not only breast cancer, but also for prostate, ovarian, and head and
neck cancer patients (reviewed Birchmeier et al. 2003, Gherardi et al. 2012).
Logically following this observation, much attention has been focused on the
identification of the protease(s) responsible for activating c-Met’s cognate ligand
pro-HGF in the breast microenvironment. (Lee et al. 2000, Owen et al. 2010,
Oberst et al. 2003). The classical activator of pro-HGF is the hepatocyte growth
factor activator (HGFA). This is a soluble serine proteinase, which is involved in
the coagulation cascade (Shimomura et al. 1997, Birchmeier et al. 2003). HGFA
is expressed in the liver and present in the blood circulation, but extensive studies
of its localization throughout the the mammary gland and other areas of the body
are lacking (Shimomura et al. 1997, Birchmeier et al. 2003, Owen et al. 2010,
Gherardi et al. 2012). Other known proteinases that activate pro-HGF are hepsin,
TMPRSS13 and matriptase (Owen et al. 2010, Hashimoto et al. 2010). Of these
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known activators, the only activators known to be expressed in the breast and in
breast tumors are matriptase and hepsin.
1.4.2 c-Met signaling
Once the c-Met receptor is activated, a number of effector proteins are
recruited, Grb2-associated binding protein 1 (Gab1), Growth factor receptorbound protein 2 (Grb2), phospholipase C and c-Src all bind directly to activated cMet. Four major signaling cascades can subsequently be activated depending on
other cellular processes and signals in the cell. The first pathway is the
Rac/Cdc42 pathway which affects integrins and cadherins, and plays a role in cell
migration and adhesion. The second pathway is the Ras-MAPK pathway, which is
linked to proliferation, cell cycle progression, migration and invasion. The
Rap/PAK pathway has been shown to activate cellular migration and invasion.
The phosphatidylinositol kinase 3 (PI3K)-Akt pathway is a classical pro-survival
pathway that has also been linked to proliferation and migration (Birchmeier et al.
2003, Gherardi et al. 2012).
These signaling outcomes of the activated c-Met impact many normal
biological functions. Discovered for its role in liver and skin regeneration, c-Met
signaling also plays major roles in cell migration during embryogenesis, wound
repair and tissue regeneration (Bladt et al. 1995, Schmidt et al. 1995, Birchmeier
et al. 2003, Gherardi et al. 2012).
Reciprocal interactions between epithelium and mesenchyme are believed
to play essential roles in breast cancer progression. Furthermore, c-Met, like
matriptase, is exclusively expressed on the surface of mammary epithelial cells.
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This pathway has been commonly shown to be dysregulated in breast cancer
patients, however the receptor itself is not often overexpressed and activation
mutations are very rare. However, it appears that signal transduction itself is
dysregulated (Ghoussaub et al. 1998, Owen et al. 2010, Raghav et al. 2012, Eder
et al. 2009). To date, dysregulated c-Met has been implicated in 32 different types
of

cancers,

including

breast

cancer

(HGF/SF-Met

in

cancer-

http://www.vai.org/met). The level of active c-Met signaling pathway factors in
patient tumors is a prognostic factor, with a 5-year survival rate of 89.6% in
patients lacking c-Met signaling in their tumors compared to only 52% for patients
that have activated c-Met signaling (Ghoussoub et al. 1998, Owen et al. 2010,
Gisterek et al. 2011, Raghav et al. 2012, Eder et al. 2009). There are 29 c-Met
inhibitors in various stages of clinical trials. These agents have increased
progression free survival and overall survival in lung cancer patients and also
show promise in other cancers as well (Reviewed in Gherardi et al. 2012).
(Clinical Trials involving HGF/SF-Met inhibitors-http://www.vai.org/metinhibitors/).
1.5 Models used to study IDC and IBC
Mouse models are powerful tools that researchers can use to analyze
mechanisms of disease in vivo. While mice can never completely mimic human
disease, the knowledge gained from various animal models is invaluable. Multiple
immortalized breast cancer cell lines are also important tools used to elucidate the
role of various molecules in vitro. Often, initial studies in cell culture models are
followed by studies in whole organism models, including mouse models. The
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following section reviews several genetic mouse models of IDC, the benefits of
xenograft models, as well as relevant human breast cancer cell line models.
1.5.1 Genetic mouse models of IDC
Numerous genetic mouse models of breast cancer have been generated
(Reviewed in Herschkowitz et al. 2007). Although 13 different models have been
developed, the three most common mouse models to specifically study IDC use
the MMTV promoter to express oncogenes in the mammary gland and include: 1)
Transgene MMTV promoter-Neu (TgMMTV-Neu), 2) TgMMTV-Wnt, 3) TgMMTVPyMT (reviewed in Hershkowitz et al. 2007 and Vargo-Gogola et al. 2007). This
promoter contains a glucocorticoid hormone response element which drives the
oncogene expression in the mammary gland (reviewed in Vargo-Gogola et al.
2007).
TgMMTV-Neu
This model expresses the activated rat homolog of the oncogene c-Neu
under the control of the MMTV promoter. The c-Neu receptor is also known as
ErbB2 or Her2 and is a member of the epidermal growth factor family.
Amplification of this gene is seen in 15-20% breast tumors in the clinic and
overexpression of c-Neu in this mouse model causes the formation of mammary
tumors (Guy et al. 1992a,b, Fantozzi et al. 2006). Since Neu is commonly
overexpressed in breast tumors, targeted treatments have been developed (See
Treatments section in breast cancer review). The MMTV-Neu model is well suited
to study the efficacy of drugs designed to target this receptor. Importantly, the
mice develop breast cancer in stages, similar to those stages observed in human
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breast cancer (Urisini-Siegel et al. 2007). Precancerous lesions in mice are called
mammary intraepithelial neoplasia (MIN) and in the TgMMTV-Neu model MIN
closely resembles DCIS (Urisini-Siegel et al. 2007, See figure 10). However,
advanced tumors induced with this model often coalesce to involve the entire
mammary gland and have a latency of roughly seven months (Muller et al. 1988,
Fantozzi et al. 2006). Overall this mouse model closely resembles human breast
cancer progression resulting in the development of mammary tumors and lung
metastasis (See figure 10). The drawbacks to using this model are that tumor
latency is roughly seven months with only a 72% lung metastasis incidence with a
latency of eight months (Reviewing in Fantozzi et al. 2006). Therefore,
comprehensively studying the natural progression of IDC in this model is timeconsuming and expensive to complete.

Figure 10: Histology showing MIN in MMTVNeu mice compared to DCIS in human. (A) and
(B) show MIN and MIN with a comedo pattern
in MMTV-Neu mice respectively compared to
DCIS and DCIS with comedo in (C) and (D).
Image rerprinted from Urisini-Siegel et al. 2007.

TgMMTV-Wnt-1
Wnt-1 was the first protooncogene to be discovered and inserted into mice
with the MMTV controlled expression mechanism (Fantozzi et al. 2006). Wnt-1 is
part of a large family of secreted intracellular signaling molecules. The major
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event of Wnt-1 signaling is to bind to the Frizzled receptors on the cell surface to
increase the level of cytosolic β-catenin. β-catenin heterodimers then translocate
to the nucleus to transactivate a number of genes, inculding c-myc, another
protooncogene (Li et al. 2000). Interestingly, Wnt-1 is not normally expressed in
the mammary gland, so in terms of oncogene expression, this model may not be
as relevant to human breast cancer as the Neu model described above (Li et al.
2000, Bocchinfuso et al. 1999). The genes that are induced by prolonged Wnt-1
expression in the MMTV-Wnt-1 model include β-catenin, c-myc, cyclin D1, Ecadherin and anaphase promoting complex (APC). Each of these genes have
been found to be either dysregulated or mutated in breast cancer (Bieche et al.
1999) The tumors formed in this transgenic model of Wnt-1 are multifocal and
also metastasize to the lymph nodes and lungs. However, the progression of
mammary cancer does not replicate the multiple stages of human breast
cancers, the pathology of these tumors present as normal or cancerous without
stages in between (Fantozzi et al. 2006, Bocchinfuso et al. 1999). Even though
Wnt1 is not normally expressed in the breast or in breast cancer, many
associated components of the Wnt-1 signaling pathway are relevant. These
include β-catenin, c-myc, cyclin D1, E-cadherin and APC making this an
appropriate model to study the effect of experimental drugs or therapies which
target these signaling molecules in breast cancer (Li et al. 2000). However, this
model also has a long tumor latency time of about eight months with only 60%
penetrance making the systems time consuming and expensive utilize. In
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addition to the long tumor latency time, the incidence of metastasis is not well
established (Li et al. 2000, Fantozzi et al. 2006).

Figure 11: Mammary gland whole mounts of mice
expressing MMTV-Wnt-1. Top panel shows a
mammary gland from a 10 week old mouse with the
expression of MMTV-Wnt-1 and the bottom panel
shows 6 month old mouse. Image reprinted and
modified with permission from Bocchinfuso et al.
1999.

TgMMTV-PymT
Perhaps the most widely used mouse model of breast cancer is the MMTV-PymT
model. The PymT oncogene, a component of the polyomavirus (PyV) family, is
essential for transformation and tumorigenesis (Fluck et al. 2009) The prolonged
expression of the PymT oncogene induces several signaling proteins associated with
breast carcinogenesis including protein phosphatase 2A (PP2A), Src family tyrosine
kinases and phosphatidylinositol kinase 3 (PI3K). Importantly, the tumors induced by
this model are multifocal and tumor development more closely resembles human breast
cancer progression than other models (Fluck et al. 2009). Another advantage to the
MMTV-PymT model is the fact that tumor progression is associated with a similar
evolution of hormone receptor status (ER, PR) to that seen in humans. Similar to human
breast cancer, early tumors in this model are largely ER and PR positive. However,
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more advanced tumors lose the expression of these receptors (Lin et al. 2003). Much
like the MMTV-Neu model, MMTV-PymT model tumors also develop similar stages
(progression model) that mimic human disease (See figure 12). This model also has the
advantage of a relatively short (average of 2 to 3 months) latency time with 100%
penetrance (Fluck et al. 2009, Fantozzi et al. 2006, Guy et al. 1992a,b). The incidence
of metastasis is also favorable with a rate greater than 85% with a latency of about 3.5
months (Fantozzi et al. 2006, Guy et al. 1992a,b). The main drawback to using the
MMTV-PymT model is that the PymT oncogene itself it not expressed in human cells.
But much like the MMTV-Wnt-1 model, this model activates a number of relevant
signaling molecules that are commonly upregulated in human breast cancers. These
include but are not limited to, c-myc, ras, cyclin D1, Cdk2 and E2F (Guy et al. 1992a,b,
Lin et al. 2003, Fluck et al. 2009). One characteristic pertaining to the MMTV-PymT
model that should be taken into consideration is the fact that tumor latency is highly
dependent on the mouse strain. This means that comparative studies should be
performed in the same background strain, and littermate controlled studies should be
used to minimize potential effects of genetic background variation (Almholt et al. 2013).

Figure 12: Shows a summary of MMTVPymT tumor progression. This model
occurs in four stages 1) Hyperplasia 2)
MIN 3) Early Carcinoma and 4) Late
carcinoma. These stages are shown as a
cartoon depiction of gross morphology, a
hematoxylin and eosin staining of tissue, a
depiction of the cellular morphology and
the biomarkers of each stage are listed at
the bottom.
Image reprinted
with
permission from Fluck et al. 2009.
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1.5.2 Xenografting Models
Xenografting is a commonly used technique where cells or tissue from one
species is transplanted into another species. In the case of breast cancer, taking
primary cells from human tumors or transplanting immortalized human breast
cancer cell lines into mice has been a successful strategy to advance our
understanding of this disease. Therefore, xenografting allows the investigation of
breast cancer cell lines or tissue in an in vivo environment that recapitulates
many tumor-stromal interactions.
However, xenografting studies must be meticulously designed and
substantial preliminary data must be obtained to appropriately estimate the
predictive power of this model (Reviewed in Sausville et al. 2006). Xenografts
can either be ectopic or orthotopic. Ectopic xenografting refers to the injection of
cells from one organ to a different site, (e.g. subcutaneous injections of breast
cancer cells). Orthotopic xenografting refers to cells that are transplanted into the
organ of origin (e.g. breast cancer cells placed into the mammary gland).
Xenografts as preclinical models for breast cancer has been used successfully to
evaluate drug activity, investigate signaling pathways and learn about protein
expression during different stages of tumorigenesis (Reviewed in Vargo-Gogola
et al. 2007).
Although xenografting models are useful in some situations, there are also
several substantial pitfalls. Xenograft models require immunodeficient mice in
which inflammatory and tumor immune responses that may be critical factors in
the pathophysiology of breast cancer progression are muted or absent. In
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addition, transplanting or injecting human breast cancer cell lines into a foreign
host (the mouse) may not recapitulate aspects of the microenvironment present
in the patient where the cancer initially developed and interacted with the
surrounding stromal compartments. For instance, in recipient mice, the
surrounding stromal cells are normal and have not adapted to support (or
suppress) cancerous growth. Depending on the parameter being studied, these
factors may affect the results and lead to inaccurate conclusions.
1.5.3 Human breast cancer cell lines
The most widely used models for breast cancer studies include human cultured
breast cancer cell lines. These cell lines are developed from tumor cells collected
from patients and kept alive in the laboratory. The cells are easily propagated, can
be genetically manipulated and, under properly controlled conditions, can supply
reproducible and quantifiable results (reviewed in Vargo-Gogola et al. 2007). Cell
lines can be grown in two dimensions or in three dimensional (2D/3D) cultures. A
drawback of using 2D culture is that the cellular microenvironment is drastically
different from that in the human breast. However one can attempt to recreate this
environment through the addition of extracellular matrix components, e.g.
collegen. 3D culture aims to mimic the tumor microenvironment by surrounding
breast cancer cells with components of the extracellular matrix and in some cases
various stromal cells (Reviewed in Vargo-Gogola et al. 2007 and Rotherberg et al.
2011). Of the numerous breast cancer cell lines that have been developed, those
most relevant to this project are listed in Table 2.
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Table 2: Relevant Breast Cancer Cell Lines:
ER

PR

Her2/Neu

c-Met

Matriptase

Subtype:

SUM229

-

-

-

+

+

IDC

HCC1937

-

-

-

+

+

IDC

BT20

-

-

-

+

+

IDC

SUM149

-

-

-

+

+

IBC

SUM190

-

-

+

+

+

IBC

SUM159

-

-

+

+

-

Anaplastic
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CHAPTER 2- MATRIPTASE MEDIATED c-MET SIGNALING IN BREAST
CANCER
2.1 Hypothesis and specific aims
The overall hypothesis of this project is that matriptase is critically involved
in breast cancer progression and exerts its oncogenic functions through the
proteolytic cleavage and activation of pro-HGF bound to c-Met, and that the
resultant sequential signaling is critical for breast cancer progression and
metastasis. To test this hypothesis three specific aims were generated:
1. Determine the significance of matriptase proteolysis in breast cancer
progression.
The working hypothesis was that matriptase plays a critical role in breast
cancer progression. To test this hypothesis, a novel matriptase loss-offunction mouse model that has been intercrossed with the MMTV-PymT
transgenic breast cancer model has been established.
The matriptase hypomorphic model, in which the levels of
matriptase protein are highly reduced in the mammary glands, was
employed to study the effect of matriptase activity on mammary
cancer progression.
2. Determine the underlying mechanism by which matriptase confers protumorigenic properties to breast cancer cells.
The working hypothesis was that matriptase activates pro-HGF to elicit an
epithelial-mesenchymal protease-mediated signaling axis where c-Met

61
signaling leads to the activation of mitogenic and invasive responses in breast
cancer cells.
a. Matriptase deficient and matriptase sufficient murine primary
mammary tumor cells were compared to determine the significance
of the matriptase-mediated activation of the HGF/c-Met signaling
pathway and the effect on cancer cell proliferation ex vivo.
b. Human breast cancer cell lines were used and matriptase
expression was manipulated by RNAi silencing and by the addition
of specific matriptase inhibitors. The ability of these cell lines to
activate

the

pro-HGF/c-Met

pathway

and

the

functional

consequences of matriptase inhibition on proliferation was
determined.
c. Patient tissue samples of IDC were used to determine the
distribution and correlation of matriptase and c-Met in human breast
cancer tissue samples.
3. Determine if matriptase proteolysis plays a role in the progression of the
least characterized type of breast cancer, inflammatory breast cancer.
The working hypothesis was that matriptase plays a similar role in
inflammatory breast cancer and intraductal breast cancer.
a. Human inflammatory breast cancer cell lines were used and
matriptase expression was manipulated manipulated by RNAi
silencing. The ability of these cell lines to activate the pro-HGF/c-
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Met pathway and the functional consequences of matriptase
inhibition on proliferation was determined.
b. Human inflammatory breast cancer cell lines were used in 3D
culture and matriptase expression was manipulated by RNAi
silencing. The ability of these cells to grow in 3D in response to proHGF was determined.
c. Tissue samples from IBC patients was used to determine the
distribution and correlation of matriptase and c-Met in human breast
cancer tissue samples.

Figure 13: Matriptase is a multi-domain
membrane
anchored serine
protease
expressed on the surface of IBC cells. The
HGF receptor, c-Met, is also expressed on
the cell surface of IBC cells. HGF is secreted
by stromal cells as an inactive precursor
(pro-HGF). Matriptase plays a critical role in
IBC progression by activating pro-HGF that
elicits an epithelial-mesenchymal proteasemediated signaling axis whereby c-Met
signaling leads to the activation of mitogenic,
morphogenic,
migratory
and
invasive
responses in IBC cells.
.
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CHAPTER 3: MATERIALS AND METHODS
3.1 Animals
All procedures involving live animals were performed in an Association for
Assessment and Accreditation of Laboratory Animal Care Internationalaccredited vivarium following institutional guidelines and standard operating
procedures. Generation of ST14 (Matriptase) hypomorphic mammary tumor
mice: Mice transgenic for the MMTV-Polyoma virus middle T oncogene (PyVT)
in the FVB/N background (strain: FVB/N-Tg (MMTV-PyVT)634Mul) were obtained
from The Jackson Laboratory (Bar Harbor, ME, USA) and crossed with females
carrying an ST14 null allele (ST14+/-) (List et al. 2002) or an ST14 knockdown/hypomorphic allele (ST14+/hypo)(List et al. 2007) in the C57BL/6
background. F1 PyVT/ST14+/- male pups were then mated to ST14+/hypo or
ST14hypo/hypo females to produce the study cohorts of F2 hypomorphic female
mice carrying the PyVT transgene, PyVT/ST14-/hypo mice (referred to as: PymTMathypo mice) and littermate control mice, PyVT/ST14+/+, PyVT/ST14+/hypo or
PyVT/ST14+/- (referred to as: PymT-Mat+ mice. Genotyping of ST14 wild-type,
knockdown, and null alleles was performed by PCR of ear or tail biopsy DNA as
described (List et al. 2002, List et al. 2007). Study animals were weighed and
palpated weekly and tumor diameters in two dimensions were obtained using
calipers. Study mice were euthanized by CO2 inhalation at 90 days, 127 days
and 145 days of age and tissues were removed for subsequent for analysis.
Generation of ST14 (Matriptase) conditional knock-out mammary tumor mice:
The generation of the conditional matriptase knockout allele (St14LoxP) as well as
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the ST14 null allele carrying a β-galactosidase expression cassette (ST14E16β-gal)
have been described previously (List et al., AJP 2006, 2009). Interbreeding of
mice carrying these St14 alleles with mice carrying a 4-hydroxytamoxifen (4OHT)-inducible

Cre

transgene

(β-actin-Cre-ERtm+/0mice,

Strain:

[B6.Cg-

Tg(Cre/Esr1)5AMC/J] Jackson Laboratories), and FVB/N-Tg (MMTV-PyVT)634Mul
mice resulted in the generation of female (MMTV-PyVT)634Mul /β-actin-CreERtm+/00;St14LoxP/E16β-gal study mice (referred to as PymT-MatCond. KO) and their
associated control littermates, (PyVT/β-actin-Cre-ERtm+/0;St14LoxP/+, PyVT/βactin-Cre-ERtm+/0;St14LoxP/E16β-gal, PyVT/β-actin-Cre-ER0;St14LoxP/E16β-gal, PyVT/βactin-Cre-ER0;St14LoxP/+(referred to as PymT-Mat+). The genotypes of all mice
were determined by PCR of ear or tail biopsy DNA as described (List et al.
2006b, 2009).
3.2 Mammary gland whole mount analysis
Mammary glands were fixed for four hours in Carnoy’s Fixative (60% Ethanol,
30% Chloroform, 10% Acetic Acid) at room temperature. The glands were then
rehydrated and stained in Carmine Alum (0.2% Carmine, 0.5% Aluminum
Potassium Sulfate) overnight. Upon dehydration, glands were cleared in xylene
and embedded in Permount Mounting Medium (Fisher Chemicals, Fair Lawn,
NJ). The area of cancerous lesions relative to the area of the entire mammary
gland was determined with Image J (NIH software).
3.3 Immunohistochemistry- Mouse tissues: Mice were euthanized by CO2
inhalation. Tissues were fixed in 10% neutral-buffered zinc formalin (Z-fix)
(Anatech, Battle Creek, MI), embedded in paraffin, and cut into 5-μm sections. The
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immunohistochemical procedures were performed as previously described (List et
al. 2009). Primary antibodies used were: sheep anti-matriptase and goat anti-c-Met
(R&D

Systems,

Minneapolis,

MN).

Cell

proliferation

was

visualized

by

intraperitoneal injection of 100µg/g bromodeoxyuridine (BrdU) (Sigma Chemical
Co, St. Louis, MO) 2 hours before euthanasia. BrdU incorporation was detected
with a rat anti-BrdU antibody (Accurate Chemical and Scientific Corporation,
Westbury, NY Alternatively, a rabbit anti Ki67 (Thermo Scientific, Logan, UT) was
used. As negative controls non-immune rabbit IgG (Sigma, St. Louis, MO) or nonimmune rat IgG were used (Sigma, St. Louis, MO). Bound antibodies were
visualized using biotin-conjugated anti-rabbit or anti-rat antibodies (Vector
Laboratories, Burlingame, CA) and a Vectastain ABC kit (Vector Laboratories,
Burlingame, CA). The 3,3’-diaminobenzidine was used as the substrate (SigmaAldrich, St. Louis, MO) and arrays were counterstained with hematoxylin. All
microscopic images were acquired on a Zeiss Scope A.1 using digital imaging.
3.4 Breast cancer tissue array
The "B20812 and “BRc711” breast cancer tissue arrays with pathology grading
were obtained from US Biomax, Inc. (Rockville, MD). Grade II and III tumors were
analyzed in this study. These two arrays contained no duplicate samples.
Immunohistochemistry was performed as previously described (Bergum et al.
2012). Primary antibodies were mouse anti-matriptase and goat anti-c-Met (both
from R&D Systems, Minneapolis, MN). As negative controls non-immune mouse
IgG (Sigma, St. Louis, MO) or non-immune goat IgG were used. Bound antibodies
was detected as described above (Section 3.3)
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3.5 Isolation of primary mammary epithelial cells and carcinoma cells
Primary mammary carcinoma cells were isolated essentially as described (Simian,
hirai et al., 2001). Briefly, tumor tissue was removed aseptically, minced and
digested with hyaluronidase (300 U/ML) (EMD Chemicals, Gibbstown, NJ) and
collagenase (2 mg/ml) (Worthington Biochemical Corporation, Lakewood, NJ)
added to growth medium: Ham’s F12:DMEM (Corning Cellgro, Manassas, VA)
supplemented with 5% FCS (Atlanta Biologicals, Lawrenceville, GA), insulin (10
µg/ml), EGF (10 ng/ml), transferin (T), (10 ug/ml) (Lonza, Walkersville, Maryland)
and hydrocortisone (10 µg/ml) (Sigma-Aldrich Chemicals, St. Louis, MO) and
incubated for 2 hours at 37OC. Normal primary mammary cells were isolated from
glands 4 and 9 (inguinal) and digested as above for 30 min at 37OC. Primary
epithelial cells or carcinoma cells were then isolated by several differential
centrifugation steps and plated in growth medium (Niranjan et al.1995,
Development). Growth medium was supplemented with Penicillin/Streptomicin/
Gentamicin (Thermo Scientific, Logan, UT).
3.6 Human breast cancer cell lines
The SUM159 and SUM229 cell lines were a gift from Dr. Stephen Ethier (Medical
University of South Carolina, Charleston, SC, USA). The HCC1937 and BT20 breast
cancer cells were purchased from ATCC (Mannassas, VA). The growth conditions
for each cell line are as follows; SUM159, SUM229 and SUM149 cells were grown in
5% IH media (Ham’s F-12 media, supplemented with 5% FBS, 1µg/ml
hydrocortisone, and 5µg/ml insulin), BT-20 cells were grown in Eagles + NEAA
media (Eagle’s MEM with 2mM L-glutamine and Earle’s BSS adjusted to contain
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1.5g/L sodium bicarbonate, 0.1mM non-essential amino acids, 1mM sodium
pyruvate, and 10% FBS), SUM190 cells were grown in SFIH media (Ham’s F-12
media, supplemented with 1µg/ml hydrocortisone, and 5µg/ml insulin, 5mM
ethanolamine, 10 mM HEPES, 5 µg/ml transferrin, 10 nM triodo-thyronine, 50 µM
sodium selenite, and 5% BSA) and HCC 1937 cells were grown in RPMI+L-GLUT
media (RPMI-1640 media with 2mM L-glutamine adjusted to contain 1.5g/L sodium
bicarbonate, 4.5g/L glucose, 10mM HEPES, 1mM sodium pyruvate, and 10% FBS).
3.7 Pro-HGF/SF activation assays
Pro-HGF/SF was produced in the immortalized human fibroblasts cell line RMFHGF as described (Kuperwasser, et al. 2004, Mueller et al. 2012). To ensure the
quality and to estimate the concentration of each preparation, western blot analysis
was performed using a goat anti-HGF primary antibody (R&D Systems,
Minneapolis, MN) with recombinant human recombinant active HGF (R&D
Systems, Minneapolis, MN) as a standard. Human breast cancer cell lines or
primary mouse MMTV-PymT mammary carcinoma cells were plated in 6- well
plates and grown to confluence. Cells were then serum starved for a minimum of
three hours. The media was then changed to either fresh serum free media, serum
free media with 100 ng/ml recombinant active two-chain HGF/SF (R&D Systems,
Minneapolis, MN) or pro-HGF/SF with or without either 2µM Aprotinin (MP
Biomedicals, LLC, Solon, OH) 20µM Leupeptin (Fisher Bioreagents, Fair Lawn,
New Jersey), 60nM HAI-1 or 40nM HAI-2 (R&D Systems). Inhibitors were added
concomitantly with pro–HGF/SF or HGF/SF. To determine the effect of Pro-HGF/SF
on activation of c-Met and downstream signaling molecules (Gab1, AKT) with time,
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the cell culture medium was aspirated at various time points and the cells were
lysed in ice cold RIPA lysis buffer (150 mM NaCl, 50 mM Tris, 1% NP-40, 0.1%
SDS, pH 7.4) with protease inhibitor cocktail and phosphatase inhibitor (Sodium
Orthovanadate, Sigma-Aldrich, St. Louis, MO). Activation levels of cMet, Gab1 and
AKT was determined by accessing the levels of the phosphorylated forms relative
to the level of the total amount of the specific signaling molecules by western
blotting analysis (see below).
3.8 3D cell culture
The 3D protocol described in Victor et al. 2011 was used. Briefly, cells were grown
under conditions listed above and then plated on Matrigel Matrix Growth Factor
Reduced (MMGFR)(BD Biosciences, Franklin Lakes, NJ) with serum free
Mammary Epithelial Cell Growth Medium (MEGM™) media (Lonza, Walkersville,
MD) containing the BulletKit™ growth supplement (BPE, hydrocortisone, GA1000, Insulin). On overlay of MEBM growth media containing 2% MMGFR was
added 1 hour after seeding. Spheroids were allowed to form overnight before
addition of 100 ng recombinant HGF/SF (R&D Biosystems, Minneapolis, MN) or
pro-HGF conditioned media. All conditions were serum free from the initial
seeding onto MMGFR. After treatment, cells were stained with 5 uM Cell Tracker
Orange (Invitrogen, Carlsbad, CA) for 45 minutes and Hoechst 33342 (Life
Technologies Carlsbad, CA) for 5 minutes prior to imaging. Confocal images were
acquired on the Zeiss LSM 780 scope at the Microscopy Imaging and Cytometry
Resources Core at Wayne State University School of Medicine. Light microscopy
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pictures were taken on the Nikon TMS microscope courtesy of Dr. Hyenong-Reh
Kim (Wayne State University, Department of Pathology).
3.9 RNAi silencing
For matriptase knockdown in SUM229, BT20 AND HCC1937 breast cancer cells,
three independent Stealth RNAiTM siRNA duplexes targeting matriptase (siM1ST14HSS186125, siM2-ST14HSS186126, siM3- ST14HSS110268), as well as
%GC matched negative controls were used as previously described (Invitrogen,
Carlsbad, CA) (Bergum et al. 2012). Two days after transfection the cells were
serum starved and used in the pro-HGF/HGF activation assay and in the 3D
invasion assay (described above in 3.7 and 3.8) and in the proliferation assay
described below (3.11)
3.10 Western blot analysis
Mouse tissues were snap frozen and homogenized in ice cold RIPA lysis buffer
(150 mM NaCl, 50 mM Tris, 1% NP-40, 0.1% SDS, pH 7.4) with protease inhibitor
cocktail added (Sigma-Aldrich, St. Louis, MO). Cultured mouse and human cells
were lysed in ice cold RIPA buffer with protease inhibitor cocktail and phosphatase
inhibitor (Sodium Orthovanadate, Sigma-Aldrich, St. Louis, MO). The protein
concentration was determined by BCA assay (Pierce, Rockford, IL) and lysates
were separated by 4–12% reducing SDS-PAGE and blotted onto polyvinylidene
difluoride membranes (Invitrogen). The following primary antibodies were used for
detection: sheep anti-matriptase (R&D Systems, Minneapolis, MN), rabbit antimatriptase (CalBioChem, Philadelphia, PA), rabbit anti-phospho cMet, anti-phospho
Gab1, anti-Gab1, anti-phospho Akt, anti-Pan Akt, mouse anti-human cMet (all from
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Cell Signaling Technology, Beverly, MA) and mouse anti-beta-actin (Sigma St.
Louis, MO). The signal was detected with secondary antibodies conjugated with
either alkaline phosphatase (Sigma St. Louis, MO) or horseradish peroxidase
(Chemicon Temecula, CA) using the chromogenic substrate nitro-blue tetrazolium
and 5-bromo-4-chloro-3'-indolyphosphate solutions (Roche, Indianapolis, IN) or
Super-SignalWest Femto Chemiluminescent Substrate (Pierce, Rockford, IL).
3.11 Proliferation assays in human breast cancer cell lines
30,000 human breast cancer cells were seeded into a six-well plate and serum
starved overnight before being treated with 100 ng active HGF or pro-HGF for 24
hours. Thereafter cells were trypsinized and recounted using a hemocytometer to
determine the proliferation of cells after treatment.
3.12 Transient transfection of SUM159 cells
SUM159 cells were plated using 106 cells/well in a 6 well plate and were transfected
when they reached 85% confluency using Lipofectamine LTX (Invitrogen, Carlsbad,
CA) according to manufacturer’s protocol. A total of 5 µg of DNA and 10 µL of LTX
was used. The DNA construct used was the mammalian expression vector,
pcDNA3.1 containing full length human matriptase DNA (a generous gift from Dr.
Stine Friis, NIH) (See Friis et al. 2013).
3.13 Matriptase gelatin zymography
Gelatin zymography for matriptase was performed as described in List et al., 2005.
Briefly, serum-free media conditioned for 2 days by primary mammary cells was
collected and dialyzed against distilled water overnight at 4°C. The dialyzed
samples were lyophilized, and the dried protein powder was dissolved in a 1/100
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volume of the initial conditioned medium in 20 mM Tris-HCl (pH 7.5). Concentrated
medium was separated by SDS-PAGE under non-reducing conditions, and the gels
(containing 0.1% gelatin) were subsequently incubated in renaturation buffer (50
mM Tris-HCl at pH 7.5, 100 mM NaCl, and 2.5% Triton X-100) for 1.5 h followed by
30 min in EDTA buffer (50 mM Tris-HCl at pH 7.5, 0.5 mM EDTA) to eliminate
matrix metalloproteinase activities as described (Jin et al. 2005). The gels were
incubated at 37°C for 16 h in developing buffer (50 mM Tris-HCl at pH 7.5 with 5
mM CaCl2), and stained with Coomassie Brilliant Blue to detect zones of
gelatinolysis.
3.14 Statistical analysis
All analysis was performed and graphs generated using Prism 5 software (GraphPad
Software Inc., San Diego, CA). Comparisons between two groups used student's t test.
Non-parametric data was compared using the Mann-Whitney test. For correlation data,
two estimators of association were used. The tetrachoric correlation coefficient assumes
that the variables, matriptase and c-Met, in this case, are normally distributed but that
they have been dichotomized. Kendall’s tau does not have the assumption of normality
and is a measure of concordance. Both measures have a theoretical range from -1 to 1.
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CHAPTER 4: EXPLANATION OF GENETIC MOUSE MODELS
Knockout mouse models have proved to be invaluable tools to determine the
functions of oncogenes, tumor suppressor genes, and other genes associated with
breast cancer progression. The perinatal lethality of matriptase null mice limits the
ability to study matriptase in an in vivo setting. We have circumvented this problem
by generating two novel genetically modified mice. This section outlines the two
mouse models used in this study.
4.1 Matriptase hypomorphic mice
The matriptase hypomorphic mice were generated by inserting a retroviral
targeting vector into the first intron of the matriptase gene (List et al. 2006b). These
mice have an 80-99% reduction in matriptase mRNA in different tissues, and
importantly have a >85% reduction of matriptase levels in the mammary gland.
Although these mice have severely reduced matriptase messenger RNA (mRNA)
levels both pre- and postnatally, these mice are viable and live a normal lifespan. It
is important to note that even with reduced matriptase levels, the residual protein is
sufficient to maintain normal epithelial function in the mammary gland and the
female hypomorphic mice are still lactation competent. By crossing these
matriptase hypomorphic mice with mice carrying the MMTV-PymT oncogene, we
performed a comparative study of breast cancer progression in mammary glands
with normal matriptase levels and mammary glands with greatly reduced matriptase
levels. In agreement with the findings in human breast carcinomas (Lin et al. 1993),
endogenous matriptase is expressed exclusively in the epithelium of the MMTVPymT tumors and is overexpressed in these malignancies. Importantly, the level of
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proteolytically active matriptase is also increased as demonstrated by gelatin
zymography
4.2 Matriptase conditional knockout mice
While the matriptase hypomorphic model represents a chronic reduced loss
of function model since matriptase levels are reduced in utero and postnatally, it is
possible that compensatory mechanisms during mammary gland development
and/or carcinogenesis, e.g. altered expression of other proteases or their inhibitors
may

occur.

In

addition,

matriptase

hypomorphic

carcinoma

cells

have

approximately 25% residual matriptase. To gain the most comprehensive insights
into matriptase functions, we therefore used the matriptase conditional knockout
mice where the matriptase gene can be acutely disrupted, rendering matriptase
protein level undetectable in mammary primary mammary carcinoma cells.
We used an inducible acute matriptase conditional knockout mouse, which
allows us to efficiently and temporally regulate matriptase ablation. This strain of
mice carries a ubiquitously expressed form of the Cre-recombinase (β-actinCreERTM) which can be activated by exposure to the synthetic estrogen antagonist
4-hydroxytamoxifen (4-OHT) but is not activated by endogenous estrogen (Hayashi
2002). Administering 4-OHT to the adult conditional knock-out mice (MatloxP/Null/ βactin-CreERTM) is lethal since the global acute matriptase ablation causes rapid loss
of cell-cell adhesions in the intestinal epithelium and the mice die after one week
(List et al. 2009). However, the mammary glands can be excised from the mice and
grown ex vivo where 4-OHT can be administered to the primary cells in culture to
induce efficient matriptase ablation (See figure 14). It is important to mention that
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the most commonly used Cre-strain for mammary specific loxP mediated
recombination, the MMTV-Cre strain, proved to be deleterious for our purpose. This
was caused by an unexpectedly high (“leaky”) expression of the MMTV-Crerecombinase in the skin of the mice. This expression led to premature death caused
by the loss of matriptase that is essential for proper epidermal function. Our
strategy was therefore to use the β-actin-CreERTM as described above. We again
crossed this strain with mice bearing the MMTV-PymT oncogene to determine the
effect of ablated matriptase expression on signaling in the cells from these
mammary tumors.
Figure 14: Matriptase in mammary gland cells upon
acute ablation. A conditional matriptase knock-out mouse
model was generated by flanking exon 2 of the mouse
matriptase gene with LoxP sites. The mice also carry a null
allele with a β-galactosidase marker gene which makes easy
identification of donor cells after transplantation possible,
TM
and a β-actin-Cre ER transgene for quick and efficient
matriptase gene inactivation upon 4-OHT administration.
Matriptase-deficient
and matriptase-sufficient
primary
mammary breast carcinomas cells (from mice with the PymT
oncogene) were isolated and cultured ex vivo to perform
western blotting to evaluate the resultant level of HGF/c-Met
signaling.
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CHAPTER 5: MATRIPTASE MEDIATED c-MET SIGNALING- RESULTS IN
INVASIVE DUCTAL BREAST CANCER
5.1 Introduction
Pericellular proteases in cancer progression were previously primarily considered
to be extracellular matrix protein degrading enzymes. While it is clear that proteases are
involved in degradation events related to breaching the basement membrane and
reorganization of the extracellular matrix, during invasive growth a more complex view
of pericellular proteolysis has emerged in recent years. One concept in protease
mechanistic research is that proteolytic modifications of targets including activation of
growth factors are critically involved in carcinogenesis through the activation of
oncogenic signaling pathways. Importantly, tumor progression is characterized by a
complex interplay between invading tumor cells and stromal cells, which, includes
paracrine pathways where growth factors secreted by stromal cells activate signaling
pathways in the cancer cells.
The type II transmembrane serine protease, matriptase, has been implicated in
breast cancer since it was first discovered in breast cancer cell lines, and is highly
expressed in the epithelium-derived cancer cells of human breast carcinomas (Lin et al.,
1997, Oberst et al., 2001, Jin et al., 2007, Bergum et al., 2012). However, it is currently
not known whether matriptase plays a critical role in breast cancer progression in vivo.
One factor that has slowed advances on this front has been the perinatal lethality of
matriptase-null mice which has thus far, precluded direct studies of matriptase loss-offunction in the mammary gland (List et al., 2002, 2003).

This obstacle has been

circumvented by employing a matriptase hypomorphic model with low levels of
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matriptase in the mammary gland. When crossed into the mouse mammary tumor virus
(MMTV) Polyomavirus middle T (PymT) mouse genetic mammary tumor model, we
show the matriptase hypomorphic mice displayed a significant delay in tumor onset and
a decreased tumor burden and tumor multiplicity. The impaired growth was caused by a
profound impairment of tumor cell proliferation.
Hepatocyte growth factor/scatter factor (HGF/SF) is a pleotrophic, paracrine
growth factor and key mediator of cell migration, proliferation, survival, motility, and
morphogenesis in epithelial cells (Weidner et al. 1991; Nakamura et al. 1989; Stoker et
al. 1987). HGF/SF is biosynthesized as a single-chain zymogen-like inactive precursor
(pro-HGF) and is proteolytically processed to its two-chain mature active form. The
epithelial cell receptor, cMet, binds pro-HGF/SF or active HGF/SF, however, only the
active form elicits the cMet signaling pathway (Cooper et al., 1984, Bottaro et al., 1991).
Proteolytic cleavage of the Arg494-Val495 peptide bond in pro-HGF results in allosteric
activation of the serine protease-like β-chain (HGF β) and the two-chain form, consisting
of a disulfide-linked α/β-heterodimer, is capable of activating cMet (Lokker et al., 1992,
Hartman et al., 1992). Pro-HGF is secreted by mesenchymal cells, mainly fibroblasts, in
the breast. Importantly, c-Met is, like matriptase, expressed on the surface of mammary
epithelial cells and breast carcinoma cells (Kang et al., 2003, Bergum et al., 2011). The
HGF/c-Met signaling pathway is dysregulated in many cancer types including breast
cancer and has been causally linked to breast carcinogenesis (Camp et al., 1999,
Ghoussoub et al., 1998, Gallego et al., 2003, Liang et al., 1996, Kang et al., 2003).
Since a key post-translational regulation mechanism of HGF/SF/c-Met signaling is the
proteolytic activation of pro-HGF/SF, the identification of the critical activator(s) as
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potential targets for therapeutic intervention in cancer is needed (Gherardi et al., 2012).
This work identifies matriptase as the essential proteolytic mediator of HGF/c-Met
signaling in breast cancer. Thus, genetic ablation of matriptase in mouse mammary
carcinoma cells leads to the lack of c-Met activation upon stimulation with fibroblast
derived pro-HGF. Silencing of matriptase in human breast cancer cells causes complete
abrogation of the c-Met signaling pathway and causes severe impairment of
proliferation and invasive responses. In sum, we demonstrate that matriptase, HGF and
c-Met define an epithelial-mesenchymal protease-mediated signaling axis where proHGF is efficiently activated on the cell surface by matriptase, leading to initiation of the
c-Met signaling pathway and elicitation of mitogenic and invasive responses in breast
cancer.
5.2 Matriptase is expressed in the epithelium of the mammary gland and
upregulated in mammary carcinoma.
Transgenic MMTV-PymT mice are predisposed to develop multifocal mammary
carcinomas with tumor progression that is very similar to that seen in human breast
carcinomas (Guy et al., 1992 a, b, Lin et al., 2003). In order to ensure that the mouse
mammary cancer model closely mimics the observations in human breast cancer,
matriptase expression in normal mammary gland and mammary tumors was
characterized (Fig. 15.). A knock-in mouse with a promoterless β-galactosidase gene
inserted into the endogenous matriptase gene was used as a unique tool for precise
assessment of endogenous matriptase expression in the mammary gland by X-gal
staining [List et al., 2007 a, b ]. Matriptase is exclusively expressed in the epithelial cells
in normal mammary glands and in the cancer cells in MMTV-PymT oncogene induced
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carcinomas with no detectable expression in the stroma (Fig. 15 A). Matriptase protein
is detected in normal primary cells at low levels and the expression is increased in
mammary carcinoma cells by western blotting (Fig. 15 B). Furthermore, matriptase is
present in its proteolytically active form in mammary epithelial cells, and the level of
active matriptase is significantly increased in mammary carcinoma cells in comparison
to normal mammary epithelial cells as demonstrated by gelatin zymography (Fig. 15 B).
Importantly, the findings that

matriptase is specifically expressed in the epithelial

compartment and upregulated during carcinogenesis is in accordance with previous
findings in human breast carcinomas (Bergum et al., 2011, Oberst et al., 2001),
rendering this tumor model particularly well-suited to understand the role of matriptase
in tumor progression in humans.
5.3 Matriptase hypomorphic mice have greatly reduced levels of matriptase in the
mammary glands.
We have previously generated matriptase hypomorphic mice (Mathypo) harboring
one ST14 null allele and one ST14 “knockdown” allele in which an engrailed-2 splice
acceptor site had been inserted between coding exons one and two (List et al., 2007 a,b
, List et al., 2006). These mice display an 80-99% reduction in matriptase mRNA levels
in different tissues and have normal postnatal and long-term survival (List et al., 2007b).
To assess the level of matriptase protein in the mammary gland of Mathypo mice,
western blot analysis of protein lysates of whole glands was performed. The level of
matriptase protein in the mammary gland in Mathypo mice is reduced >75% (Fig. 15 C)
as compared to littermate control mice (Mat+). Immunohistochemical staining of
mammary glands confirmed that matriptase protein expression in the ductal epithelium
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FIGURE 15: EXPRESSION OF MATRIPTASE IN THE MMTV-PymT MAMMARY
CARCINOMA MODEL AND IN THE MATRIPTASE HYPOMORPHIC MODEL
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(A) A knock-in mouse with a promoterless β-galactosidase marker gene inserted
into the endogenous matriptase gene was used as a unique tool for precise
assessment of endogenous matriptase expression in the mammary gland by Xgal staining (blue color). Matriptase is expressed in the mammary gland
epithelium (arrowhead in A) with no detectable expression in the stroma (*) in
whole mounts from normal glands (left panel) and MMTV-PymT induced
carcinomas (middle panel). Histological analysis shows matriptase expression in
the mammary cancer cells of MMTV-PymT transgenic mice (arrowhead, right
panel) (B). Mammary epithelial cells from normal glands and tumor bearing
glands were isolated and analyzed by western blotting (top panel) and gelatin
zymography (lower panel) demonstrating increased levels of active matriptase in
mammary carcinoma cells. (C) Western blot analysis of whole mammary gland
extracts from matriptase hypomorphic mice (Mathypo) and control (Mat+)
littermates with anti-matriptase (upper panel) or anti-HAI-1 antibodies. The levels
is greatly reduced in the Mathypo mice (Fig. 15 D). Importantly, the residual matriptase in
the of the epithelial specific, physiological matriptase inhibitor, HAI-1, is

comparable in Mathypo and Mat+ littermate mice. (D) Relative matriptase
expression in Mathypo (N=3) and Mat+ mice (N=3) as determined by densitometry.
Matriptase levels were normalized to HAI-1. Error bars represent S.D. P<0.04,
Student’s T-test.
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is greatly reduced in the Mathypo mice (Fig. 15 D). Importantly, the residual matriptase in
the mammary gland suffices to sustain normal mammary gland development based on
comparative morphological and histological assessment (data not shown). Furthermore,
Mathypo females have functional mammary epithelium since they are lactation
competent, and no reduction in litter size or litter survival has been observed. Thus, this
model is well-suited to study progression of breast cancer in morphologically and
functionally normal mammary glands with greatly reduced levels of matriptase.
5.4 Reduced matriptase leads to impairment of mammary carcinogenesis.
To investigate the effects of low matriptase levels in the mammary gland on
mammary carcinoma progression, matriptase Mathypo and Mat+ mice harboring the
MMTV-PymT oncogene were generated (referred to as PymT-Mathypo and PymT-Mat+
mice, respectively). Prospective cohorts with littermate PymT-Mathypo and PymT-Mat+
virgin female mice was established and carefully monitored by weekly palpation to
determine the appearance of the first palpable mammary mass (tumor latency). At 145
days of age the number of glands with visible and palpable tumors was recorded (tumor
multiplicity) and the area of tumors was determined by caliber measurements. Total
mammary tumor burden was calculated as the total weight of all postmortem excised
mammary glands from a cohort of littermates.
Reduced levels of matriptase in the mammary glands had significant effects on
all the tumorigenesis parameters measured (Fig. 16). Thus, the total tumor burden was
reduced by 58% (mean tumor burden of PymT-Mat+, 2.6 g; PymT-Mathypo,1.1 g) and the
total tumor area was reduced by 76% (mean tumor area in PymT-Mat+, 2.9 mm2/day;
PymT-Mathypo , 0.7 mm2/day). Also, tumor multiplicity was reduced by 45% (mean
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number of glands with tumors in PymT-Mat+, 4.0; PymT-Mathypo, 2.2). These results
demonstrate that matriptase is an important contributor to tumor growth and
progression. Importantly, there was a significant delay in initial formation of palpable
mammary indicating that matriptase is critical for early carcinogenesis with a mean
latency of palpable tumors of 84 days in PymT-Mat+ versus 120 days in PymT-Mathypo
mice. At 90 days 53% of PymT-Mat+ mice had palpable tumors versus 21% of PymTMathypo mice. In order to examine the role of matriptase in early mammary
carcinogenesis in further detail, an independent cohort was established and dysplastic
lesions in the inguinal mammary gland were examined postmortem by whole mount
analysis at 90 days of age. Importantly, total area measurements of lesions revealed a
75% reduction in the glands from PymT-Mathypo mice as compared to PymT-Mat+ (Fig.
16 F). Taken together, these data strongly supports a functional role for matriptase in
both tumor formation and tumor growth.
5.5 Reduced matriptase impairs carcinoma cell proliferation in mammary tumors
To address the basis for the diminution of mammary tumor growth in mice with
low matriptase, proliferation rates of carcinoma cells were determined at two different
time points by immunohistochemical detection of bromodeoxyuridine (BrdU) or
endogenous Ki67 (Figure 17). At 127 days of age carcinoma cell proliferation was
reduced by 47% in PymT-Mathypo mice as compared to PymT-Mat+ mice. A dramatic
decrease in proliferation was also observed in PymT-Mathypo 145 day old mice with an
81% reduction as compared to littermate PymT-Mat+ mice. These data strongly suggest
that matriptase-dependent carcinoma cell proliferation promotes mammary tumor
growth.
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FIGURE 16: REDUCED MATRIPTASE DECREASES MAMMARY TUMOR BURDEN,
GROWTH RATE, LATENCY AND MULTIPLICITY
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A prospective cohort of littermate PymT- Mat+ mice (N=13) and PymT Mathypo
mice (N=14) was followed (A) Tumor burden at 145 days. Mice were euthanized
and their mammary tumors resected and the total tumor weight was recorded for
PymT Mat+ mice (closed circles) and PymT-Mathyop mice (open circles). Mean
values were 2.6 and 1.1, respectively (P < 0.002) Mann-Whitney U Test. (B)
Mammary tumor growth rate for PymT-Mat+ mice (closed circles) and PymTMathypo mice (open circles). Mean values were 2.9 and 0.7, respectively (P <
0.0001) Mann-Whitney U Test. (C) Kaplan-Meier tumor-free survival curves of
PymT-Mat+ (black line) and PymT-Mathypo (grey line).The median tumor-free
survival times were 89 days versus 122 days, respectively (P < 0.007) ChiSquared Test (D) Total number of glands with lesions at 145 days for PymTMat+ mice(closed circles)and PymT-Mathypo mice (open circles). Mean values
were 4.0 and 2.2, respectively (P < 0.0001) Mann-Whitney U Test. (E)
Representative whole mounts of inguinal mammary glands from 90 day old virgin
female littermates. Normal mammary epithelia in Mat+ gland (upper panel).
Extensive growth of multiple lesions (arrowheads) in PymT-Mat+ gland (middle
panel), small localized lesion (arrowhead) in PymT-Mathypo gland (lower panel).
LN=Lymph node. (F) Total area of lesions in 18 inguinal mammary glands from
PymT-Mat+ (closed circles) and 15 PymT- Mathypo (open circles) (P < 0.0001)
Mann-Whitney U Test.
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FIGURE 17: DECREASED CARCINOMA CELL PROLIFERATION IN
MAMMARY TUMORS WITH REDUCED MATRIPTASE
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(A) Representative pictures of mammary tumors from PymT-Mat+ (top) and
PymT-Mathypo (bottom) stained with an anti-BrdU antibody. Mice were injected
with BrdU two hours prior to euthanasia. Size bars, 50 µm. (B) Quantification of
carcinoma cell proliferation in 127 day old mice. Data are presented as the mean
relative number of cells with positive nuclear BrdU staining in tumors from PymTMat+ (N=4, black bars), and littermate PymT-Mathypo mice (N=3, white bars)
Error bars represent S.D. P<0.001, Mann-Whitney U Test (C) Quantification of
carcinoma cell proliferation in 145 day old mice. Data are presented as the mean
relative number of cells with positive nuclear Ki67 staining in tumors from PymTMat+ (N=4, black bars), and littermate PymT-Mathypo mice (N=4, white bars).
P<0.001, Mann-Whitney U Test. Error bars represent S.D.
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5.6 Genetic ablation of matriptase abolishes pro-HGF induced c-Met signaling in
primary mammary carcinoma cells.
An important task to undertake in order to gain mechanistic insight into the
pathophysiological functions of matriptase is to identify the critical proteolytic target(s).
Of the candidate substrates for matriptase that have been identified thus far, pro-HGF
has been shown to directly promote mammary carcinogenesis. Thus, in a transgenic
mouse model with overexpression of pro-HGF in the mammary gland, hyperplastic
ductal trees with highly proliferative epithelial cells and subsequent development of
multifocal invasive tumors were observed (Gallogo et al., 2003). Also, pro-HGF/HGF is
a prognostic marker in human breast cancer where elevated expression is associated
with poor prognosis (Camp et al., 1999, Ghoussoub et al., 1998, Gallego et al., 2003,
Liang et al., 1996, Kang et al., 2003]. Pro-HGF is expressed by stromal mammary
fibroblasts in both human and mice (Niranjan et al., 1995).

To date, no genetic

matriptase loss-of-function studies have been published, determining whether
matriptase is critical for pro-HGF activation and c-Met signaling in cancer. Therefore, we
chose to employ specific gene ablation to determine whether matriptase is required for
efficient pro-HGF activation and elicitation of the c-Met signaling pathway in breast
cancer. For this purpose MMTV-PymT-induced primary mammary carcinoma cells from
conditional matriptase knock-out mice carrying a ubiquitously expressed inducible Cre
recombinase (PymT-Matcond.ko) which allows for permanent inactivation of floxed
matriptase alleles upon brief exposure to 4-hydroxy-tamoxifen (4-OHT)(List et al.,
2009). As shown in Figure 18 A, efficient matriptase ablation was induced ex vivo in
PymT-Matcond.ko mammary carcinoma cells rendering matriptase protein undetectable by

86
western blotting. Upon exposure to serum free media conditioned with fibroblastsecreted pro-HGF (Kupperwasser et al. 2004), c-Met activation was assessed by
western blotting using antibodies against phosphorylated c-Met (p-c-Met). In matriptase
sufficient PymT-Matcontrol cells robust c-Met activation was observed (Fig. 18 B). In
addition, activation of the two down-stream cytoplasmic effector proteins: Gab1 and
AKT (also known as Protein Kinase B) was observed. In contrast, activation of c-Met,
Gab1 and AKT was efficiently abrogated in PymT-Matcond.ko mammary carcinoma cells.
Importantly, when cells were stimulated with pre-cleaved two-chain active HGF,
matriptase deficiency did not affect phosphorylation of c-Met, Gab1 and AKT (Fig. 18).
This strongly suggests, that the effects of matriptase gene ablation on cell signaling is
caused by the loss of matriptase-mediated proteolytic conversion of pro-HGF to active
HGF and thereby the ability to initiate the c-Met signaling pathway. Also, in a parallel
control experiment, where primary PymT-Matcontrol and PymT-Matcond.ko carcinoma cells
from the same primary cell isolation batches as used above were treated with vehicle
instead of the gene recombination-inducing agent, 4-OHT, matriptase expression was
not affected and the cells responded to pro-HGF expression by phosphorylation of cMet, Gab1 and AKT, (Supplementary figure 1) demonstrating that the cells have the
inherent ability to cleave pro-HGF and activate c-Met signaling prior to matriptase gene
ablation.
Both Gab1 and the PI3K–AKT pathway are important regulators of cell
survival and proliferation downstream from pro-HGF/c-Met activation. Based on
the finding that matriptase is critical for their activation, it is plausible that
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matriptase promotes mammary tumor proliferation via initiation of the c-Met
signaling network.
5.7 Matriptase silencing causes abrogated c-Met signaling and proliferation in
human invasive ductal breast cancer cell lines.
In order to verify the relevance of matriptase-dependent pro-HGF activation in
human breast cancer, three different human breast cancer cell lines of diverse origin
were employed: BT20 (invasive ductal carcinoma, triple negative), SUM229 (pleural
effusion, triple negative) and HCC1937 (invasive ductal carcinoma, triple negative). All
three cell lines express matriptase and c-Met (Fig. 19 A and Supplemental Fig 2).
Matriptase was efficiently silenced using three independent non-overlapping matriptase
silencing synthetic RNA duplexes in all three human breast cancer cell lines. Addition of
pro-HGF to HCC1937 matriptase sufficient control cells resulted in robust activation of
c-Met and the downstream targets Gab1 and Akt (Fig. 19 B). In contrast, matriptase
ablation led to a greatly reduced level of c-Met pathway activation rendering the
phosphorylated forms of c-Met, Gab1 and Akt undetectable by western blotting.
Importantly, the matriptase silenced cells display unaltered activation of the c-Met
pathway upon stimulation with pre-cleaved active HGF, demonstrating that the
matriptase deficient cells have a fully functional c-Met signaling pathway and that the
impaired response to pro-HGF is due to the lack of the matriptase-mediated activation
cleavage (Fig. 19 B). Similar results for BT10 and SUM229 cells upon matriptase
silencing were observed including efficient abrogation of the activation of c-Met, Gab1
and Akt (Supplemental Fig 2). This indicates that the mechanism observed is not limited
to one cell line and may represent a general phenomenon in human breast cancer.
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FIGURE 18: ABROGATION OF ACTIVATED c-MET AND DOWNSTREAM
SIGNALING PROTEINS IN MATRIPTASE DEFICIENT PRIMARY MAMMARY
CARCINOMA CELLS
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(A) Efficient temporally controlled Cre-mediated ablation of matriptase in primary
mammary carcinoma cells as demonstrated by western Blot analysis of primary
cells isolated from virgin female mammary glands from PymT-Matcond KO or
PymT-Matcontrol mice. Two days after plating 10 µM 4-OHT (+) or vehicle (-) was
added to the culture medium for 24 hours. Hereafter, the cells were kept in
serum-free medium without 4-OHT for another 24 h before lysis and separation
by reducing SDS-PAGE. A sheep anti-matriptase antibody was used for
detection. Skin lysates from a newborn matriptase null mouse and wild-type
littermate were included as controls for antibody specificity. Anti- beta-actin was
used as control for equal loading (B) Mammary carcinoma cells were isolated
from PymT-Matcond KO and treated with 4-OHT as above to ablate matriptase
expression (vehicle treated cells shown in S1) and exposed to active HGF (2
mins) or pro-HGF (0, 10 or 20 mins). Cells were lysed and analyzed for total cmet, activated c-Met, and its downstream targets by western blotting.
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FIGURE 19: MATRIPTASE IS REQUIRED FOR ACTIVATION OF THE PROHGF/c-MET SIGNALING PATHWAY AND PROMOTES CELL
PROLIFERATION IN INVASIVE DUCTAL BREAST CANCER CELLS
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(A) Efficient RNAi silencing of matriptase in HCC1937 cells with three
independent non-overlapping synthetic RNA duplexes (siM1, siM2 and siM3). A
%GC matched negative control was used as negative control as well as a mock
where no RNA duplex was added. Beta-actin staining of the membrane was
performed to ensure equal protein loading (B) Cells were serum staved and
exposed no HGF (serum free media), active HGF (2 min) or pro-HGF (15 min).
Cells were lysed and analyzed for total c-met, activated c-Met, and its
downstream targets by western blotting. (C) HCC1937 cells were grown on
culture plates and matriptase was silenced using three independent nonoverlapping synthetic RNA duplexes (siM1, siM2 and siM3). A %GC matched
negative control was used as negative control. The cells were serum starved and
left untreated (black bars) or exposed to either active HGF (gray bars) or proHGF (white bars) 24 hours and counted. Graphs show the proliferation at 24
hours after stimulation (*P<0.04, **P<0.005, ***P<0.0008, Student’s T-Test).
Data represent mean of three replicates. Error bars represent S.D.
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To assess the functional consequences of inhibiting the matriptase-meditated cMet signaling in human breast cancer cells, a proliferation assay was performed.
As described above, matriptase was silenced with three different synthetic RNA
duplexes, counted and seeded on cell culture plates and stimulated with proHGF or active HGF. After 24 hours the cells were recounted. As expected, there
was no significant growth difference in matriptase sufficient control cells treated
with active HGF or pro-HGF. In contrast, the growth in matriptase silenced cells
was significantly impaired in response to pro-HGF in comparison to the response
observed in HGF. These results demonstrate that silencing matriptase leads to
decreased pro-HGF activation and subsequent c-Met signaling pathway
activation ultimately causing growth inhibition. Taken together, with the results for
mouse mammary carcinoma described above we have demonstrated that
matriptase is the major, and perhaps the only, efficient activator of pro-HGF in
models systems using either primary carcinoma cells or three established
carcinoma cell lines. This conclusion is supported by the fact that no apparent
compensation by one or more proteases upon genetic ablation or posttranscriptional silencing of matriptase was detected.
5.8 Matriptase re-expression restores c-Met signaling in human breast cancer
cells in response to HGF.
The SUM159 cell line was established from a primary breast anaplastic
carcinoma. Interestingly, SUM159 cells have lost the expression of endogenous
matriptase and are non-responsive to pro-HGF (Fig. 20). Importantly, SUM159
cells have retained the proliferation response capability upon stimulation with
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two-chain active HGF. To investigate whether re-expression of matriptase could
re-store the ability to respond to pro-HGF, SUM159 cells were transiently
transfected with a mammalian expression vector containing human full-length
matriptase. When SUM159 cells with very low endogenous matriptase
expression were exposed to pro-HGF and subsequently analyzed by western
blotting, no phosphorylated c-Met, Gab1 or Akt were detected. In contrast,
SUM159

expressing

full-length

matriptase

displayed

readily

detectable

phosphorylation of c-Met, Gab1 or Akt upon exposure to pro-HGF. The
matriptase-mediated ability to activate the c-Met signaling pathway was
accompanied by a strong mitogenic response to pro-HGF (Fig. 20 C). This
demonstrates that gain-of-function matriptase expression confers SUM159
breast cancer cells with the capability of activating pro-HGF and thereby elicits
the c-Met signaling pathway and subsequent proliferative response.
5.9 Matriptase mediates pro-HGF induced invasion in human invasive ductal
breast cancer cell lines.
Many cancer cell lines form spontaneous three dimensional (3D) multicellular
tumor-like spheroids when cultured in reconstituted basement membrane (rBM) overlay
culture.

These spheroids often resemble solid tumors, and tumorigenic processes

including invasive growth, can therefore studied in this model system.
HGF is also named scatter factor (SF) because of its ability to induce
scattering of MDCK cells involving the disruption of cell-cell junctions and an
increase in motility in 2D culture, and formation of branching tubules when
embedded in collagen (Stoker et al., 1987, Montesano et al., 1991). Since then
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FIGURE 20: RE-EXPRESSION OF MATRIPTASE IN HUMAN INVASIVE
DUCTAL BREAST CANCER CELLS INDUCES ROBUST c-MET SIGNALING
AND PROLIFERATION
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(A) The matriptase deficient human breast cancer cell line, SUM159 was
transfected with an expression vector containing full-length matriptase.
Beta-actin staining of the membrane was performed to ensure equal
loading. (B) Cells were serum starved and exposed to active HGF or proHGF for the time periods indicated. Cells were lysed and analyzed for total
and activated c-Met and downstream signaling proteins by western blotting.
(C) SUM159 cells were grown on culture plates and matriptase transfected
in using an expression vector containing full-length human matriptase. The
cells were serum starved and left untreated (black bars) or exposed to either
active HGF (gray bars) or pro-HGF (white bars) for 24 hours and counted.
Graphs show the proliferation at 24 hours after stimulation (*P<0.04,
**P<0.005, ***P<0.0008, Student’s T-Test). Data represent mean of three
replicates. Error bars represent S.D.
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FIGURE 21: MATRIPTASE MEDIATES PRO-HGF INDUCED INVASION IN
HUMAN INVASIVE DUCTAL BREAST CANCER CELLS
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SUM229 cells were grown on culture plates and matriptase was silenced (Mat
KD) using synthetic RNA duplexes (B, B’, B’’). A %GC matched negative control
was used as negative control (A, A’, A’’). Cells were allowed to form spheroids in
3D rBM overlay culture for 24 hours before addition of either pro-HGF (A’, B’),
HGF (A’’, B’’) or no treatment (A, B) and imaged by confocal microscopy. When
no HGF was added, control and Mat KD spheroids remained intact (black
arrowheads). In contrast, addition of pro-HGF induced extensive invasive
outgrowths in matriptase sufficient control cells (A’) (indicated with open
arrowheads) whereas the majority of Mat KD remained intact (B’). Both control
and Mat KD responded to active two-chain HGF (A’’’, B’’’). Cells were labeled
with Cell Tracker Orange and nuclei with Hoechst (blue). (C) 3D rBM cell cultures
were scored for the number of intact spheroids when left untreated (black bars)
or exposed to either active HGF (white bars) or pro-HGF (white bars). Data
represent mean of the number of intact spheroids before treatment relative to the
number after treatment (*P<0.04, Student’s T-Test). Error bars represent S.D.
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HGF/SF has been shown to induce invasiveness in a variety of cancer cells in 3D
cultures, we used the 3D model system to assess the invasive response of matriptase
sufficient and matriptase deficient human breast cancer cells in response to pro-HGF.
When SUM229 cells were grown in rBM overlay culture they spontaneously formed
spheroids (Fig. 21 A). Upon stimulation with pro-HGF for 24 hours, matriptase sufficient
control cells displayed pronounced invasive growth characterized by branching cellular
structures and single cells with a flattened spindle-like appearance. Matriptase silencing
in SUM229 spheroids (Mat KD) rendered the cells unresponsive to pro-HGF, thus,
keeping the vast majority of the cells confined in compact spheroid structures (Fig. 21 A,
B and Supplemental figure 3). Similar observations were made using HCC1937 cells
(data not shown). Addition of pre-cleaved active HGF restored the ability of matriptasedeficient cells to respond to pro-HGF. These data demonstrate that matriptase, in
addition to promoting breast cancer cell proliferation as described above, potentiates
the invasive capacity of cancer cells suggesting that matriptase-mediated c-Met
signaling is critical for several pro-tumorigenic processes.
5.10 Matriptase and c-Met expression are strongly correlated in human invasive
ductal breast carcinomas.
To investigate whether the functional link identified between matriptase and cMet is likely to represent a general molecular pro-tumorigenic mechanism in human
breast cancer, the expression of matriptase and c-Met in a large sample set of 153
(grades I-III) human invasive ductal carcinoma tumor tissue was analyzed by
immunohistochemistry (IHC) (Fig. 22). The staining of invasive ductal carcinomas was
strong and uniform for both matriptase and c-Met in the cancer cells. Furthermore, the
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staining patterns observed for matriptase and c-Met were strikingly similar, consistent
with co-localization between the two proteases in breast carcinomas (Fig. 22). No
significant staining was observed in tumor stromal compartments. The vast majority of
tumor samples, 88% (134/153), displayed detectable expression of both matriptase and
c-Met protein. A small subset of tumors 7% (11/153), displayed no detectable
expression of neither matriptase nor c-Met, whereas 5% (7/153) of the breast tumors
expressed matriptase but not c-Met. In only 0.7% (1/153) of the tumors was c-Met but
not matriptase protein detected. The overall comparison of groups showed a highly
significant correlation between matriptase and c-Met expression in breast cancer
(p<0.001). Importantly, co-expression of matriptase of and c-Met was also consistently
observed in MMTV-PymT tumors validating this breast tumor model as being highly
relevant for studying the matriptase/pro-HGF/c-Met signaling axis (Supplementary
Figure. 4). The finding that matriptase and c-Met are both expressed in the vast majority
of the human invasive ductal carcinomas analyzed, presents the opportunity of potential
therapeutic intervention in a large number of breast cancer patients.
5.11 Inhibition of matriptase proteolytic activity abrogates pro-HGF induced c-Met
signaling in mouse mammary carcinoma cells and human invasive ductal breast
cancer cell lines.
Based on our findings that matriptase is critically involved in breast cancer cell
proliferation

and

invasion,

and

tumor

progression

and

growth in

vivo, this

protease represents a promising target for drug development. To determine whether
inhibition of matriptase proteolytic activity leads to abrogation of the c-Met signaling
activation, three matriptase inhibitors were tested in murine and human breast cancer
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cell culture models. Leupeptin is a broad spetrum small peptide, reversible protease
inhibitor. HAI-1 and 2 are reversible, competitive macromolecular Kunitz-type serineprotease inhibitors that haven been shown to be physiological inhibitors of matriptase
(Benaud et al., 2001, Szabo et al., 2008, 2009a, 2009b). In addition, HAI-1 and 2 have
previously been shown to inhibit several members of the TTSP family in vitro including
matriptase, matriptase-2, HAT, hepsin and TMPRSS13, however, the physiological
relevance of the inhibition of these proteases remains unknown (Maurer et al., 2013,
Hashimoto et al., 2010, Tsai et al, 2013, Kato et al., 2011). When leupeptin was added
to primary mouse mammary carcinoma cells concomitantly with pro-HGF, a significant
inhibition of c-Met activation was observed (Fig. 23 A). A similar effect was seen in the
three human breast cancer cell lines BT20, HCC1937 and SUM229 (data not shown).
HAI-1 and HAI-2 also inhibited c-Met activation in both murine and human breast cancer
cells (Fig. 23 A, B and data now shown). In sum, the development of selective and
efficient inhibitors of matriptase proteolytic activity represents a new avenue for
targeting the pro-tumorigenic c-Met signaling pathway by inhibition of the matriptasedependent conversion the signaling-inert single-chain pro-HGF to a signaling-competent
two-chain HGF.
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FIGURE 22: MATRIPTASE AND c-MET ARE CORRELATED IN HUMAN INVASIVE
DUCTAL CARCINOMAS
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Representative staining of serial sections of invasive ductal carcinoma (A-C)
using a mouse monoclonal anti-matriptase antibody (A) and a goat anti-cMET
antibody (C) Primary antibodies were substituted with non-immune isotype
control mouse IgG (B) or non-immune goat IgG (D) as negative controls Both
matriptase and c-Met (brown staining, arrows) is detected in the cancer cells
(indicated with “C”) with no significant staining in the mesenchymal/stromal
compartments (indicated with “S”). Both proteases are primarily localized on cell
surfaces and in the cytoplasm and display highly similar expression patterns. (E)
Expression of matriptase and c-Met in 153 human invasive ductal carcinomas.
Bars depicts the frequency of samples expression both matriptase and c-Met
87% (134/153) samples that express neither of the two proteases 7% (11/153),
samples that express only matriptase 5% (7/153) and samples that express cMet only as indicated 1% (1/153). The overall comparison of groups showed a
highly significant correlation between c-Met and matriptase expression:
Tetrachoric Rho=0.95 (P<0.001).
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FIGURE 23: INHIBITION OF MATRIPTASE ACTIVITY IMPAIRS THE c-MET
PATHWAY ACTIVATION IN PRIMARY MAMMARY CARCINOMA CELLS AND
HUMAN INVASIVE DUCTAL BREAST CANCER CELL LINES
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(A) Mouse mammary carcinoma cells were isolated from Mat-PymT+ mice and
exposed to active HGF or pro-HGF with and without matriptase inhibitors added
concomitantly (60 nM HAI-1, 40 nM HAI-2 and 20 uM Leupeptin). Cells were
lysed and analyzed for activated c-Met by western blotting. (B) Human breast
cancer (HCC1937, SUM229 and BT20) cell lines were plated, serum starved and
exposed to active HGF, pro-HGF or pro-HGF with 40 nM HAI-2 added
concomitantly for 10, 20 and 30 minutes. Cells were lysed and analyzed for total
and activated c-Met by western blotting.
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CHAPTER 6: MATRIPTASE MEDIATED c-MET SIGNALING IN BREAST CANCERRESULTS IN INFLAMMATORY BREAST CANCER
6.1 Introduction: Targeting matriptase/c-Met in inflammatory breast cancer
Inflammatory breast cancer is a rare and aggressive form of invasive breast
cancer accounting for approximately 5% of breast cancer cases annually in the United
States. IBC is characterized by rapid progression, local and distant metastases,
younger age of onset, and lower overall survival compared with other breast cancers.
IBC is a lethal disease with a 5-year survival rate of 40% when treated with surgery, or
radiation therapy. IBC patients often present with a breast that looks inflamed due to
extensive lymphovascular invasion of tumor emboli which block lymphatic drainage from
the breast, but no palpable tumor. The rapid development of metastases with IBC
results from high proliferative rates and potent ability for angiogenesis and
lymphangiogenesis.
Studies of extracellular proteolysis in breast cancer progression have mainly
focused on the most common form of breast cancer; non-IBC invasive ductal
carcinoma. To date, no studies have assessed the expression and potential procancerous role of matriptase in IBC. Based off the promising results in the IDC breast
cancer and an on-going collaboration with Dr. Julie Lang, a breast cancer surgeon at
the University of Southern California, we expanded the previous experiments to human
IBC breast cancer cell lines and obtained IBC patient tumor samples.
6.2 Matriptase silencing causes abrogated c-Met signaling and proliferation in
human inflammatory breast cancer cell lines.
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It has been demonstrated that matriptase can cleave and activate the pro-form of
HGF. However, no studies describing a role for matriptase as a pro-HGF activating
protease in breast cancer have been published. To determine whether matriptase
regulates c-Met activation via activation of pro-HGF, SUM149, and SUM190 cells were
stimulated with pro-HGF or active HGF and the phosphorylation/activation state of cMet and the downstream targets, Gab-1 and AKT, were analyzed. The source of proHGF was serum free conditioned media from human reduction mammoplasty fibroblasts
expressing human HGF (RMF-HGF) (Kupperwasser et al., 2004). In the first set of
experiments, two physiological inhibitors of matriptase:HAI-1 and HAI-2 were employed.
SUM149 and SUM190 cells were serum starved and stimulated with pro-HGF with
either HAI-1 or HAI-2 added concomitantly. Both inhibitors efficiently abrogated
activation of the c-Met activation pathway (data not shown). Since it cannot entirely be
excluded that HAI-1 or HAI-2 inhibits one or more additional proteases in IBC cells,
experiments using RNAi mediated silencing of matriptase were performed. Efficient
RNAi silencing of matriptase with three independent non-overlapping synthetic RNA
duplexes was achieved in SUM149 and SUM190 cells (Fig. 24 A and B). Addition of
pro-HGF to matriptase sufficient control cells resulted in robust activation of c-Met and
the downstream targets Gab1 and Akt (Fig. 24A’ and 3B’). In contrast, matriptase
ablation led to a greatly reduced level of c-Met pathway activation (to levels not
detectable by western blotting).

Importantly, the matriptase silenced cells display

unaltered activation of the c-Met pathway upon stimulation with pre-cleaved active HGF,
demonstrating that the impaired response to pro-HGF is due to the lack of matriptasemediated cleavage and not caused by an unforeseen RNAi effect on c-Met functionality
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per se (Fig. 24A’ and B’, second panel). The similar findings in two different IBC cells
indicates that the mechanism observed may represent a general phenomenon in IBC.
Again, the functional consequences of abrogating the activation of the c-Met
pathway was assessed (Fig. 24 A’’’). The growth in matriptase-silenced cells was
significantly impaired in response to pro-HGF in comparison to matriptase sufficient
cells. No significant difference in growth response to HGF was observed between
matriptase sufficient and matriptase deficient cells. These results demonstrate that
silencing matriptase leads to decreased pro-HGF activation and subsequent c-Met
signaling pathway activation ultimately causing growth inhibition in inflammatory breast
cancer cells. Taken together, with the results for mouse mammary carcinoma described
above we have demonstrated that matriptase is the major, and perhaps the only,
efficient activator of pro-HGF in these inflammatory carcinoma cell lines.
6.3 Matriptase mediates pro-HGF induced invasion in human inflammatory breast
cancer cells.
Additionally, we used the 3D model system to assess the invasive response of
matriptase sufficient and matriptase deficient human inflammatory breast cancer cells in
response to pro-HGF. When SUM149 cells were grown in rBM overlay culture they
spontaneously formed spheroids (Fig. 25 A). Upon stimulation with pro-HGF for 24
hours, matriptase sufficient control cells displayed pronounced invasive growth
characterized by formation of branching, invasive multi-cellular structures. Matriptase
silencing in SUM149 spheroids (Mat KD) rendered the cells unresponsive to pro-HGF,
thus, keeping the vast majority of the cells confined in compact spheroid structures (Fig.
25 A, B). Addition of pre-cleaved active HGF restored the ability of matriptase-deficient
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cells to respond to pro-HGF. These data demonstrates that matriptase, in addition to
promoting breast cancer cell proliferation as described above, potentiates the invasive
capacity of inflammatory breast cancer cells suggesting that matriptase-mediated c-Met
signaling is critical for several pro-tumorigenic processes.
6.4 Matriptase and c-Met are both expressed in human inflammatory breast
carcinomas.
A prerequisite for matriptase and c-Met to be functionally linked in vivo is that they
are expressed in close proximity to each other, on either the same cell or neighboring
cells. Therefore, an important component to elucidate the roles of matriptase and cMet in IBC is to determine their expression and localization in IBC patient samples.
We have performed immunohistochemistry using two different anti-matriptase
antibodies and observe staining in infiltrating cancer cells and in the cancer cells of
lymphatic emboli from IBC patient samples (Fig. 26 and data not shown). We have
also verified that c-Met protein is detected in IBC (Fig. 26) in accordance with a
study by Garcia and colleagues (Garcia et al. 2007). As of yet, there are no data
assessing the extent of co-localization in cancer cells of IBC tumors, or regarding
whether co-expression is widespread or confined to certain areas. Therefore, a
comprehensive expression analysis on serial sections is needed. However,
preliminary data below provide a solid foundation to execute the experiments
needed to determine if matriptase and c-Met are correlated in human inflammatory
breast carcinomas.
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FIGURE 24: MATRIPTASE IS REQUIRED FOR ACTIVATION OF THE PROHGF/c-MET SIGNALING PATHWAY AND PROMOTES CELL
PROLIFERATION IN INFLAMMATORY BREAST CANCER CELLS
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Efficient RNAi silencing of matriptase in SUM149 cells (A) and SUM190 cells (B)
with three independent non-overlapping synthetic RNA duplexes (siM1, siM2 and
siM). A %GC matched negative control was used as negative control as well as a
mock where no RNA duplex was added. Beta-actin staining of the membranes
was performed to ensure equal protein loading SUM149 cells (A’) and SUM190
cells (B’) were serum staved and exposed to no HGF (serum free media), active
HGF (2 min) or pro-HGF (15 min). Cells were lysed and analyzed for total c-met,
activated c-Met, and its downstream targets by western blotting. Sum149 cells
(A”) were grown on culture plates and matriptase was silenced using three
independent non-overlapping synthetic RNA duplexes (siM1, siM2 and siM). A
%GC matched negative control was used as negative control. The cells were
serum starved and exposed to either active HGF or pro-HGF for 24 hours and
counted. Graphs show the proliferation at 24 hours after stimulation (*P<0.04,
**P<0.005, ***P<0.0008)
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FIGURE 25: MATRIPTASE MEDIATES PRO-HGF INDUCED INVASION IN
HUMAN INFLAMMATORY BREAST CANCER CELLS
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SUM149 cells were grown on culture plates and matriptase was silenced (Mat
KD) using synthetic RNA duplexes (B, B’, B’’). A %GC matched negative control
was used as negative control (A, A’, A’’). Cells were allowed to form spheroids in
3D rBM overlay culture for 24 hours before addition of either pro-HGF (A’, B’),
HGF (A’’, B’’) or no treatment (A, B) and imaged by confocal microscopy. When
no HGF was added, control and Mat KD spheroids remained intact (black
arrowheads). In contrast, addition of pro-HGF induced extensive invasive
outgrowths in matriptase sufficient control cells (A’) (indicated with open
arrowheads) whereas the majority of Mat KD remained intact (B’). Both control
and Mat KD responded to active two-chain HGF (A’’’, B’’’). Cells were labeled
with Cell Tracker Orange and nuclei with Hoechst (blue). (C) 3D rBM cell cultures
were scored for the number of intact spheroids when left untreated (black bars)
or exposed to either active HGF (white bars) or pro-HGF (white bars). Data
represent mean of the number of intact spheroids before treatment relative to the
number after treatment (*P<0.04, Student’s T-Test). Error bars represent S.D.
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FIGURE 26: MATRIPTASE AND c-MET ARE EXPRESSED IN HUMAN
INFLAMMATORY CARCINOMAS
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Representative examples of staining of IBC paraffin sections samples with
mouse anti-matriptase (A, C, D) and goat anti-met antibodies, respectively. Nonimmune matching IgG were included as negative controls respectively (B, F).
Matriptase staining is detected in infiltrating IBC cells (A), peritumoral emboli (C)
and dermal lymphatic emboli (D). Expression of c-Met observed in dermal emboli
(E).
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CHAPTER 7: DISCUSSION AND FUTURE DIRECTIONS
Matriptase is an epithelial cell-surface protease that is highly expressed in human
breast cancer. In this project, the specific functions of matriptase in mammary
tumorigenesis were investigated by using a validated mouse model of human ductal
mammary adenocarcinoma (Maglione et al. 2001; Lin et al. 2003).

Mice with low

matriptase expression in the mammary epithelium displayed a significant delay in tumor
onset, tumor burden and multiplicity. Importantly, a significant abrogation of tumor
progression was seen in early stages of carcinogenesis, where total area
measurements of lesions revealed a 75% reduction in the matriptase hypomorphic
mammary glands. In late stage carcinogenesis, the total tumor burden was reduced by
58%. A major contributing factor to tumor growth impairment was the dramatic decrease
of carcinoma cell proliferation in matriptase hypomorphic tumors. To elucidate the
molecular mechanisms underlying matriptase-mediated proliferation, an ex vivo model
where primary mammary carcinoma cells were isolated from tumors and grown outside
the body for no more than one week and without passaging was utilized. This model
has the benefit of being short-term and therefore fewer cellular changes caused by
adaptations to cell culture conditions are expected.
HGF/SF is an important promoter of proliferation and invasion in cancer and its
receptor c-Met, like matriptase, is expressed in the epithelial compartment of the breast.
The inactive pro-form binds to the c-Met tyrosine kinase receptor where it, upon
proteolytic cleavage, is converted to the signaling-competent active form. HGF
mediated c-Met signaling activates multiple downstream targets including the PI3/AKT
pathway and the c-Met adapter protein, Gab1. Until now, the protease responsible for
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pro-HGF activation in breast cancer has not been identified. Using matriptase deficient
primary mammary carcinoma cells this work demonstrates that matriptase is essential
for activation of fibroblast secreted pro-HGF and initiation of downstream c-Met
signaling. This finding was confirmed using matriptase silencing in three different human
IDC cell lines and 2 human IBC cells lines, as well as matriptase re-expression in one
human IDC cell line. In addition, these data demonstrate that the functional
consequence of matriptase abrogation is severe impairment of proliferation and
invasion in breast cancer cell lines. This work concludes that matriptase-mediated proHGF activation and c-Met signaling is critical in breast cancer cells from both mice and
human, and that this mechanism is conserved in two very different human breast cancer
types as well as in an array of breast cancer cells lines with different origins and
characteristics.
Since breast cancer cells express a variety of extracellular proteases, it is
somewhat surprising that none of these appear to be capable to cleave and activate
pro-HGF in mouse primary mammary carcinoma cells or human breast cancer cells
when matriptase expression is ablated. Hepatocyte growth factor activator (HGFA) has
been reported to be expressed in multiple breast cancer cell lines and in human breast
tumors (Parr et al. 2001). It should be mentioned, that despite its name, no evidence
has been presented that implicates HGFA as a physiological relevant pro-HGF
activator. In genetic targeting studies in mice, both HGF null and c-Met null mice display
an embryonic lethal phenotype, whereas HGFA-null mice develop normally to term and
have no discernable phenotype in adult mice (Bladt et al. 1995, Uehara et al. 1995, Itoh
et al. 2004). That suggests that HGFA is dispensable as a pro-HGF activator during
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development and postnatal life. Studies assessing the role of HGFA in tumorigenesis in
vivo have not been published.
Two TTSP’s, hepsin and TMPRSS13, that have previously been reported as
being able to cleave and activate pro-HGF in vitro, were readily detected by Western
blot analysis in a variety of breast cancer cells lines (unpublished data). These included
HCC1937, SUM229, BT20, SUM190 and SUM149 used in this study for matriptase
silencing studies. Since no or minimal residual pro-HGF activity was detected upon
matriptase silencing, it is unlikely that these proteases act as efficient pro-HGF
activators on the cell surface of breast cancer cells. It can be argued that acute
matriptase ablation may not allow breast cancer cells time to mobilize compensatory
mechanisms. Countering this possibility is the fact that the SUM159 cell line that has
lost endogenous matriptase and remains undetectable through several years and
multiple passages, expresses high levels of both hepsin and TMPRSS13, yet requires
transgenic re-expression of matriptase in order to respond to pro-HGF stimulation.
Several scenarios could be imagined to explain why matriptase is the most efficient
cellular pro-HGF activator. In in vitro experiments using recombinant soluble activate
forms of hepsin and matriptase, hepsin is approximately 10 fold less efficient than
matriptase in activating pro-HGF, whereas matriptase and HGFA display similar
efficiency (Owen et al. 2010). However, the level of active matriptase in comparison to
active hepsin or active HGFA in breast cancer cells is not known. Also, matriptase is
able to efficiently cleave pro-HGF on the cell surface (Owen et al. 2010) which may give
matriptase an advantage over HGFA, a soluble protease, as activated HGF can be
specifically generated at its site of action. It remains to be determined whether the
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membrane localization of matriptase provides the protease with a kinetic advantage and
whether the stem-region domains are involved in substrate recognition or interaction
with c-Met. Thus, factors including activation state, membrane-anchoring, localization in
cell membrane microdomains, and interaction between protease and c-Met could favor
matriptase in certain cellular microenvironments including breast cancer.
Based on these studies, the development and testing of selective matriptase
inhibitors may represent a new avenue for targeted therapy in breast cancer. As
demonstrated, matriptase is critically involved in the activation of c-Met dependent protumorigenic processes in vivo, ex vivo and in breast cancer cell lines. Importantly, the
fact that matriptase and c-Met display a strong correlated expression in human breast
tumors suggest that targeting the matriptase-mediated c-Met signaling cascade has the
potential for broad clinical application. One factor to consider is the potential side-effects
of matriptase inhibition in patients. Based on studies in mouse genetic models, the skin
and the gastrointestinal tract would like be the most sensitive tissues where matriptase
targeted drugs could cause adverse effects. However, hypomorphic mice which have
less than 1% residual epidermal and intestinal matriptase and display only a mild and
temporary ichthyosis of the skin in very young mice, and a mild gut barrier defect with
no discernible consequences for adult mouse health (List et al. 2005, Buzza et al.
2012). Furthermore, humans with a hypomorphic mutation in the ST14 gene, resulting
in a matriptase mutant protein with a 1000-fold lower activity than that of wild-type
matriptase resulted in a mild temporary ichthyosis in the skin and brittle hair of affected
children with significant improvement with age. No gastrointestinal symptoms were
reported (List et al. 2007, Basel-Vanagaite et al. 2007). It is therefore plausible that
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matriptase function in normal physiological functions in humans is predominantly critical
during childhood and that targeted inhibition in adults have few and mild adverse
effects.
In a recent article by a group of researchers that originally identified c-Met and
since made seminal contributions regarding the biochemical properties, structure and
functions of c-Met in development and disease, the rationale and progress of targeting
c-Met in cancer is reviewed (Gheradi et al. 2012). The c-Met inhibitors developed thus
far include c-Met antagonists such as antibodies that bind to c-Met and competes with
pro-HGF/HGF binding, and c-Met kinase inhibitors. Some of the c-Met kinase inhibitors
are highly selective for c-Met, whereas others target additional receptors such as
VEGFR-2 and platelet-derived growth factor receptor-β (PDGFRβ). The authors
mention targeting of pro-HGF activating proteases as potential novel inhibitors of c-Met
signaling and that resistance to kinase inhibitors may be circumvented by combining
inhibitors with different modes of action.
The majority of c-Met inhibitors used in clinical trials are still under evaluation,
however, promising results have been achieved in non-small cell lung cancer where
patients with high c-Met expression showed increased progression-free survival when
treated with a monoclonal anti-c-Met antagonistic antibody in combination with an
EGFR-inhibitor (erlotinib) than with erlotinib alone (Spigel et al. 2011). In breast cancer,
studies with the multi-target c-Met inhibitor XL184 (also known as cabozantinib) have
shown significant activity (Gordon et al. 2011).
In an effort to evaluate the anti-tumorigenic properties of small-molecule
matriptase inhibitors, a collaboration with Drs. Leduc, Marsault and Richter at the
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Universitѐ De Sherbrooke, Québec, Canada has been initiated. This group has
designed and synthesized a series of potent and selective matriptase inhibitors that
have not previously been tested in cancer cell experiments (Colombo et al. 2012).
Initially, the efficacy of the inhibitors will be tested for their ability to inhibit matriptasemediated pro-HGF activation, c-Met signaling and proliferation in human breast cancer
lines. The long-term plan is to test the anti-tumorigenic potential of selected inhibitors in
mouse breast cancer models.
In conclusion, the data obtained in the dissertation work presented here
demonstrates that matriptase is critical for breast carcinoma progression using multiple
in vivo, ex vivo and cell culture approaches. Importantly, a mechanistic understanding of
the pro-cancerous properties matriptase has been reached by identifying matriptase as
an essential activator of pro-HGF and initiator of the c-Met signaling pathway. The
findings described here have laid the groundwork for future studies testing smallmolecule matriptase inhibitors and their potential as novel targeted therapeutic drugs in
breast cancer.
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APPENDIX A: SUPPLEMENTARY FIGURES
Supplementary Figure 1: Activation of c-Met and downstream signaling
proteins in matriptase sufficient primary mammary carcinoma cells.
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Mammary carcinoma cells were isolated from PymT-Matcond KO and treated with vehicle
for 24 hours (4-OHT treatment shown in Figure 4) and exposed to active HGF (2 mins)
or pro-HGF (0, 10 or 20 mins). Cells were lysed and analyzed for total c-met, activated
c-Met, and its downstream targets by western blotting.
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Supplementary Figure 2: Matriptase is required for activation of the pro-HGF/cMet signaling pathway and promotes cell proliferation in BT20 and SUM229
breast cancer cell lines.
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Efficient RNAi silencing of matriptase in Bt20 cells (A) and SUM229 cells (B) with three
independent non-overlapping synthetic RNA duplexes (siM1, siM2 and siM3). A %GC
matched negative control was used as negative control as well as a mock where no
RNA duplex was added. Beta-actin staining of the membranes was performed to ensure
equal protein loading Bt20 cells (A’) and SUM229 cells (B’) were serum staved and
exposed to no HGF (serum free media), active HGF (2 min) or pro-HGF (15 min). Cells
were lysed and analyzed for total c-met, activated c-Met, and its downstream targets by
western blotting. Bt20 cells (A”) and SUM229 cells (B”) were grown on culture plates
and matriptase was silenced using three independent non-overlapping synthetic RNA
duplexes (siM1, siM2 and siM3). A %GC matched negative control was used as
negative control. The cells were serum starved and exposed to either active HGF or
pro-HGF for 24 hours and counted. Graphs show the proliferation at 24 hours after
stimulation (*P<0.04, **P<0.005, ***P<0.0008)
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Supplementary Figure 3: Matriptase mediated pro-HGF induced invasion in
human breast cancer cells.
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SUM229 cells grown on culture plates and matriptase was silenced (Mat KD) using
synthetic RNA duplexes (B, B’, B’’). A %GC matched negative control was used as
negative control (A, A’, A’’). Cells were allowed to form spheroids in rBM overlay culture
for 24 hours before addition of either pro-HGF (A’, B’), HGF (A’’, B’’) or no treatment (A,
B). When no HGF was added, control and Mat KD spheroids remained intact (black
arrowheads). In contrast, addition of pro-HGF induced extensive scattering and invasion
in matriptase sufficient control cells (A’)(indicated with open arrowheads) whereas the
majority of Mat KD remained intact (B’). Both control and Mat KD responded to active
two-chain HGF (A’’, B’’)
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Supplementary Figure 4: Matriptase and c-Met are expressed in mouse mammary
tumors.
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Representative examples of immunohistochemical analysis of serial sections of
invasive ductal carcinoma in the mammary gland of PymT-Mat+ mice using a sheep
anti-matriptase antibody (A) and a goat anti c-Met antibody. Both matriptase and c-Met
(brown staining, arrows) is detected in the cancer cells with no significant staining in the
stromal compartment (*). Matriptase and c-Met are primarily localized on cell surfaces
and display highly similar expression patterns. Inserts; high magnification photos or
indicated tumor areas. Slides were counterstained with hematoxylin.
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ABSTRACT
MATRIPTASE MEDIATED c-MET SIGNALING IN BREAST CANCER
by
GINA ZORATTI
May 2014
Advisor: Dr. Karin List
Major: Cancer Biology
Degree: Doctor of Philosophy
Historically proteases have been associated with tumor progression and
metastasis through degradation of the basement membrane. However, in recent years
these enzymes have also been shown to play key roles in the activation of growth
factors and cytokines, thereby activating pro-oncogenic signaling pathways. Matriptase
(MT-SP1, ST14) is an epithelia-specific pericellular protease which has received
considerable attention in recent years spurred by the consistent dysregulation of the
protease in human epithelial tumors including breast cancer. We have performed both
functional and mechanistic studies of matriptase in breast cancer using parallel,
complementary in vitro and in vivo genetic “loss-of-function” strategies. To determine
the contribution of matriptase to breast cancer in vivo we used matriptase hypomorhic
mice with very low matriptase expression in the mammary gland. When crossed into
the mammary tumor virus (MMTV) Polyomavirus middle T (PymT) mouse genetic
mammary tumor model, matriptase hypomorphic mice displayed a significant decrease
in tumor burden.
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The hepatocyte growth factor (HGF)/c-Met signaling pathway is dysregulated in
breast cancer and has been causally linked to breast carcinogenesis. It has previously
been shown that matriptase is an effective activator of the inactive pro-form of HGF. To
investigate whether matriptase mediated pro-HGF activation and elicitation of the c-Met
signaling pathway plays a critical role in breast cancer we isolated primary mammary
carcinoma cells from conditional matriptase knock-out mice carrying the β-actin-Cre
ERTM transgene. Upon brief exposure to tamoxifen, matriptase was efficiently
genetically ablated allowing for comparative analysis of c-Met phosphorylation/activation
in matriptase sufficient and deficient primary carcinoma cells. Addition of pro-HGF to
matriptase sufficient cells resulted in robust activation of c-Met and the downstream
targets Gab1 and Akt. In contrast, matriptase ablation led to a greatly reduced level of cMet pathway activation. Parallel experiments using RNA silencing of matriptase in four
different human breast cancer cell lines similarly demonstrated abrogation of c-Met
signaling upon pro-HGF stimulation.

This abrogation of the c-Met signaling pathway

affects the breast cancer cells proliferation rate as well as their invasiveness as
demonstrated in 3D culture.
Our results suggest that matriptase is critically involved in pro-HGF activation
leading to downstream signaling and elicitation of mitogenic, migratory and invasive
responses in breast cancer.

143
AUTOBIOGRAPHICAL STATEMENT
Gina Zoratti
EDUCATION
Wayne State University Detroit, MI 2010-2014
Doctor of Philosophy: Cancer Biology
Michigan State University East Lansing, MI 2006-2010
Bachelor of Science: Lyman Briggs Molecular Genetics and Genomics
PUBLICATIONS
Bergum, C*., Zoratti, G*., Boerner J. & List, K. Strong expression association between
matriptase and its substrate prostasin in breast cancer. J Cell Physiol 227, 1604-1609,
doi:10.1002/jcp.22877 (2012) *equal contribution
Miller G, Zoratti G and List K. Type-2 membrane serine proteases: Physiological
functions and pathological aspects. Matrix proteases in health and disease. Editor: N.
Behrendt. Wiley-VCH STM-Books. (2012)
Mueller, KL., Madden JM, Zoratti G, Kuperwasser C, List K, Boerner JL. Fibroblastsecreted hepatocyte growth factor mediated epidermal growth factor receptor tyrosine
kinase inhibitor resistance in triple negative breast cancers through paracrine activation
of Met. Breast Cancer Research, 14(4), R104 (2012).
Miller G., Zoratti G., Murray A., Bergum C., Tanabe L., List K. HATL-5: A cell surface
serine protease differentially expressed in epithelial cancers. PLOS ONE. In Press
Zoratti G., Bergum C., Kupperwasser C., Lang J., Boerner J, List K. Matriptase
mediated c-Met signaling is critical for breast cancer progression. Manuscript in
progress.

	
  

